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Abbreviations 
ABTS Azinodiethyl-benzthiazoline-sulfonate 
ACN Acetonitrile 
APC Antigen presenting cells 
BSA Bovine serum albumin 
CatD Cathepsin D 
CatE Cathepsin E 
CF Cytosolic fraction 
CI Competitive inhibition 
CIITA (MHC) Class II transactivator 
CIIV Class II vesicles 
CPP Cell penetrating peptide 
ddH2O 
DC 
Distilled and deionized water  
Dendritic cells 
DMSO Dimethylsulfoxide 
Dnp Dinitrophenyl 
EF Endosomal fraction 
ELISA Enzyme-linked immunosorbent assay 
FITC Fluorescein isothiocyanate 
Fmoc N-(9-Fluorenyl) methoxycarbonyl 
FRET Fluorescence resonance energy transfer 
HOBt 1-Hydroxybenzotriazol 
IC50 Inhibitory concentration (50%) 
Ii Invariant chain 
IP Immunoprecipitation 
LF Lysosomal fraction 
LPS Lipopolysaccharide 
MALDI Matrix-assisted laser desorption ionisation 
Mca (7-methoxycoumarin-4-yl)acetyl 
MHC Major histocompatibility complex 
MS Mass spectrometry 
NAG N-acetyl-β-D-glucosaminidase 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PepA Pepstatin A 
RP Reversed Phase 
RP-HPLC Reversed phase-high performance liquid chromatography 
TAPA Total aspartic proteinase activity 
TBTU 
 
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate 
tBu Tert.-butyl 
TFA Trifluoroacetic acid 
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Tris 
TTC 
Tris(hydroxymethyl)aminomethane 
Tetanus toxoid C-fragment 
UV Ultraviolet 
 
 For peptide sequences the one- or three-letter amino acid code was used. SI units and standard 
abbreviations are not explained in the abbreviation list. Figures and tables are numbered for 
each chapter separately. If not otherwise stated, the mentioned figure and table numbers refer to 
the figures and tables in the same chapter 
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Preface 
Cathepsin E and D are the major aspartic proteases of endolysosomal pathway. The main focus 
of this PhD thesis was to study biochemical properties and roles of these proteases in MHC class 
II pathway. To achieve these goals different new tools were designed and characterized because 
existing ones i.e. the inhibitors or substrates were not able to discriminate between cathepsin E 
and D. In order to give this PhD dissertation a more structured and intelligible contour it is 
divided into various chapters. This format should facilitate the readers who are interested in a 
specific part of the work to find all relevant information easily. 
Chapter 1 of this PhD thesis provides the background for the understanding of the work that 
follows. This chapter has been partly published as a mini-review in BBRC (2008), 367, 517-522.  
One of the main technical hitches in studying the role and biochemical properties of cathepsin E 
and D is the lack of specific substrates for either cathepsin. The two enzymes have similar 
enzymatic properties and it is difficult to distinguish between their activities. Chapter 2 
describes the development of a new assay to differentiate between the activities of cathepsin E 
and D in endosomal and lysosomal fractions from different cell lines. This chapter has also been 
published in The FEBS Journal (2007), 125, 392-9. 
Selective inhibition of enzymes is a valuable tool for investigating their physiological functions. 
However, aspartic protease inhibitors, including the highly potent pepstatin A (PepA), are 
inefficiently transported across the cell membrane and thus have limited access to antigen 
processing compartments. Chapter 3 describes the synthesis and usefulness of our new cell 
penetrating inhibitors of aspartic proteases that were synthesized by coupling of PepA to most 
frequently used cell-penetrating peptides. In this chapter involvement of aspartic proteases in 
antigen processing pathway is also reported. This chapter has been published in BBRC (2007), 
14;364(2):243-9. 
Isolated cathepsin E is normally most active at acidic pH, but according to some previous reports 
its activity has also been observed at neutral pH. Chapter 4 of this thesis deals with this 
interesting phenomenon. In this study proteolytic potential of recombinant cathepsin E was 
examined and it was found that recombinant CatE does not have any proteolytic activity at 
Preface 
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neutral pH even in the presence of ATP that is known to stabilize this enzyme. This chapter is 
published in BBRC (2007), 17;360(1):51-5. 
To deal with the problem of unavailability of specific substrate for cathepsin E and D in a more 
detailed and comprehensive way, substrate profiling of the two enzymes was performed. This 
study is described in Chapter 5. 
The last chapter (Chapter 6) summarizes the key findings and conclusion of this PhD 
dissertation and also gives some future perspectives for research in this field. 
All the chapters in this dissertation represent the state-of-the-art when the respective manuscripts 
were prepared for publication and have been supplemented with the most relevant recent 
findings. 
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1. General introduction 
A related manuscript has been published in 
Biochem Biophys Res Commun. 367, 517-522 (2008) 
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athepsins represent a growing family of endocytic proteases with different substrate 
specificity and tissue distribution. The term “cathepsin” was first introduced in the 
1920s . However, the earliest record on "cathepsin" found in PubMed dates back to 
1934 in the  Journal of Biological Chemistry [1]. The term “cathepsin” stands for 
“endosomal/lysosomal proteolytic enzyme”, regardless of the enzyme class. Cathepsins include 
cysteine proteases, aspartic proteases and serine proteases and are involved in a number of 
important biological processes such as intracellular protein turnover, immune response and 
antigen processing, proprotein and hormone activation, remodeling of extracellular matrix and 
apoptosis [2-5]. 
Antigen presentation via major histocompatibility complex class II (MHC II) is tightly linked 
with the proteases residing within the endocytic pathway. These proteases participate in two 
main events in antigen presentation; first, processing of exogenous antigens into small 
antigenic peptides and second invariant chain (Ii) processing, as the antigen binding groove of 
class II molecules is blocked by Ii at the time of synthesis, and MHC II molecules can bind to 
antigenic peptides only after Ii has been degraded [6-9]. Cathepsins which constitute a major 
portion of this proteolytic system have been found to have essential roles in both, antigen 
processing and maturation of MHC II molecules.  
Role of cysteine cathepsins in MHC class II pathway has been more extensively studied and it 
is reported that cathepsin B, C, X, H, L and S have a clear function in the immune system, with 
cathepsins L and S being the only ones with non-redundant roles [10].  
Involvement of aspartic proteases in MHC II pathway is also reported. Cathepsin E (CatE, E.C. 
3.4.23.34) and cathepsin D (CatD, E.C. 3.4.23.5) are two major endolysosomal aspartic 
proteases and both of these enzymes have been found to play different roles in the MHC class 
II pathway [11-15]. Cathepsin E and cathepsin D show significant sequence homology and 
share similar enzymatic properties [16, 17]. However, their different tissue distribution and 
cellular localization strongly suggest that both enzymes might have different physiological 
functions. Table 1 depicts differences and similarities between the two enzymes.  In the 
following sections of this introductory chapter the important features, regulation, biological 
C 
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aspects and especially possible roles of cathepsin E and D (in MCH II pathway) will be 
discussed. Furthermore, the principal aims of the presented study are also illustrated. 
 
Table 1. Similarities and differences between cathepsin E and cathepsin D 
Characteristics Cathepsin D Cathepsin E 
pH Range 2-5 [18-20] (pH optimum is 
around pH 4.0) [19]. 
1-5.5 [19-21] (pH optimum is around 
pH 4.0 [19]). CatE is also reported to 
restore its activity by ATP at pH 
values above 5.8 [22]. Few studies 
have reported different cleavage 
specificity of CatE at neutral pH 
values [23, 24].However, we have 
recently reported that recombinant 
CatE does not exhibit any proteolytic 
activity at neutral pH and is not 
stabilized by ATP. 
Susceptibility to 
inhibitors 
Pepstatin A Pepstatin A,  Ascaris pepsin inhibitor 
[25, 26] 
Substrate Affinity Prefers aromatic amino acid at 
P1 and P1´ positions [20], 
leucine is strongly favored at 
P1, the hydrophobic requirem-
ents are less strict at P2 and P1´ 
[27]. A charged preferably basic 
residue is found mostly at 
positions P2´and P5´; at least 1 
basic residue appears to be 
required by CatD at either 
position [27]. 
P1 and P1` positions must be occupied 
with hydrophobic amino acids with 
aromatic or aliphatic side chains. Val 
and Ile residues are not allowed at P1. 
Position P2´accepts a broad range of 
amino acids, including charged and 
polar ones [28]. The presence of 
proline at the P4 might be important 
[17].Few studies reported a shift in 
cleavage specificity at neutral pH with 
special preference for Arg-Arg bonds 
[23].However, we have recently 
reported that recombinant enzyme 
does not show any proteolytic activity 
at neutral pH. 
Cellular distribution Widely distributed in almost all 
mammalian cells [29-32]. 
Mainly present in cells of the immune 
system including gastric epithelial 
cells [33], antigen presenting cells 
such as lymphocytes [29], microglia 
[34] and dendritic cells [12]. Not 
present in resting B-lymphocytes [35]. 
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Table 1 continued. 
Characteristics Cathepsin D Cathepsin E 
Subcellular localization Lysosome [29-32]. Mature enzyme is localized in 
endosomes [34]. CatE is also reported  
to be localized in plasma membranes 
[36], endoplasmic reticulum and Golgi 
apparatus [30, 34, 37]. 
 
Disease Association 
 
Pathological condition 
developed in mice- 
deficient in CatD/CatE. 
 
 
 
Over expression of the 
enzyme observed 
 
 
Massive intestinal necrosis [38], 
thromboembolia [38], lymphop-
enia [38], and neuronal ceroid 
lipofuscinosis [39]. 
 
 
Prostrate [40], breast [41] and 
ovarian cancer [42]. 
 
 
Atopic dermatitis like skin lesions 
[43], increased susceptibility to 
bacterial infections associated with 
decreased expression of multiple 
surface Toll like receptors [44], 
lysosomal storage disorder [45]. 
 
Pancreatic ductal adenocarcinoma 
[46]. 
 
 
1.1 Overview of cathepsin E 
Cathepsin E (CatE, EC 3.4.23.34) is an intracellular aspartic protease of the pepsin superfamily. 
CatE is highly homologous to the analogous aspartic protease cathepsin D. Early reports 
implicated the presence of an aspartic protease distinct from cathepsin D in vertebrate cells 
[47]. Different designations for this enzyme have been suggested, such as cathepsin D-like 
proteinase [48, 49], gastric mucosa non-pepsin acid proteinase [50], slow moving proteinase 
[51] and erythrocyte membrane acid proteinase [52]. Later, it was shown that all of these 
activities were mediated by the same enzyme, which was termed cathepsin E (reviewed in 
[47]).  
In this section the findings regarding the expression, biochemical properties and functions of 
cathepsin E are summarized and the discrepancies and similarities in the conclusions drawn by 
different groups are highlighted. 
Overview of Cathepsin E 
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1.1.1 Tissue distribution and subcellular localization 
Cathepsin E is mainly present in cells of the immune system, including antigen-presenting cells 
(APC) such as lymphocytes [29], microglia [34], dendritic cells [12], Langerhans cells [53], 
interdigitating reticulum cells [53] and human M cells [54]. Cathepsin E is not present in 
resting B-lymphocytes but is up-regulated late in human B cell activation at both, the mRNA 
and protein level [35]. It has also been detected in gastric epithelial cells [48] and osteoclasts 
[36]. Furthermore, tissue-specific distribution of CatE is not the same in different  mammalian 
species, e.g. it has been detected in red blood cells from humans and rats, but not guinea pigs, 
cattle, goats or pigs [55]. 
The intracellular localization of cathepsin E also appears to vary according to cell type. In 
APC, such as microglia [56], dendritic cells [12] and macrophages, CatE is mainly present in 
endosomal compartments. In contrast, in erythrocytes [52, 57, 58], gastric cells [30, 48, 49, 51], 
renal proximal tubule cells [30], and osteoclasts [36], it is found in the plasma membrane. CatE 
is also detected in ER and Golgi complex in different cell types, such as gastric epithelial cells 
[30, 51], Langerhans cells, interdigitating reticulum cells [53] and human M cells [54]. 
1.1.2 Activity and specificity 
1.1.2.1 Active sites 
CatE possesses two homologous domains, each containing the highly conserved tripeptide 
sequence DTG. These two domains are involved in the formation of the active site [59-61]. 
There is a high degree of similarity between eukaryotic members of the aspartic protease 
family, and their DTG sequence domains are virtually identical. The DTG sequence is present 
in all species with the exception of rabbit CatE, in which the tripeptide sequence near the N-
terminal region is replaced by DTV [62]. Liu et al synthesized active site mutants of CatE by 
site-directed mutagenesis to examine the significance of these residues [63]. They found that in 
mouse CatE, Asp98, Asp283, and Thr284 are indeed critical for catalysis [63]. 
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1.1.2.2 Specificity 
Cathepsin E, like cathepsin D, prefers hydrophobic amino acids at the P1 and P1` positions 
[47]. β-Branched residues, e.g. Val and Ile, are not allowed at P1 [28]. Position P2´ accepts a 
broad range of amino acids, including charged and polar ones [28]. For CatE, the basic residue 
e.g. Lys is acceptable at position P2, which is not the case for CatD [64]. The presence of 
proline at P4 might be important [17].  
According to some reports, CatE also retains activity at neutral pH and shows a distinct 
cleavage specificity [23, 24]. In one of these reports [24], proteolytic activity and cleavage 
specificity of CatE towards the B chain of oxidized insulin was examined. It was reported that 
the cleavage specificity changed significantly, with more specific cleavage at pH 7.4 and 
above, as compared to pH 5.5 and 3.0. At acidic pH, several peptide bonds, especially Phe-X, 
Tyr-X and Leu-X were cleaved, whereas at pH 7.4 the Glu13-Ala14 bond was selectively 
cleaved. In a more recent study [23], preferential cleavage of Arg-X and Glu-X bonds at pH 7.4 
was reported, with the Arg-Arg bond to be the preferred cleavage site. However, in all studies 
reporting proteolytic activity of CatE at pH 7.4, the enzyme was isolated either from human 
gastric mucosa [22-24] or human red blood cells [22]. In our recent study, we investigated 
proteolytic potential of recombinant cathepsin at neutral pH [65]. Our results fail to reveal any 
proteolytic activity of recombinant CatE at neutral pH even in the presence of ATP, which is 
known to stabilize this enzyme (for details see chapter 4). 
1.1.2.3 Assays 
The most common assay for measuring aspartic protease activity in biological samples employs 
acid-denatured bovine hemoglobin as substrate [52, 66, 67]. Enzymatic reaction liberates 
trichloroacetic acid-soluble products from hemoglobin which are detected by their absorbance 
at 280 nm and by the Folin reaction. This method is time-consuming and has the additional 
disadvantage that it cannot discriminate CatE activity from other aspartic proteases.  
Several synthetic chromogenic or fluorogenic substrates have been developed to measure CatE 
activity [19, 68-70]. These methods are simple and fast, but the described substrates are 
restricted in their selectivity. Recently, a new selective substrate for cathepsin E based on the 
Overview of Cathepsin E 
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cleavage site sequence of α2-macroglobulin has been described [20]. However, this substrate 
was also not exclusive for CatE because it had low level of activity for CatD and pepsin as 
well. 
Recently, we have developed a new approach for distinguishing cathepsin E and D activity in 
subcellular fractions [71]. In this method we made use of a new monospecific CatE antibody 
and substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [where Mca 
is (7-methoxycoumarin-4-yl)acetyl and Dnp is dinitrophenyl]. This substrate is digested by 
both, cathepsin E and cathepsin D and therefore can be used to detect the total aspartic 
proteinase activity (TAPA) in biological samples [19]. CatE is depleted from the samples by 
immunoprecipitation using this new highly specific antibody and the remaining activity is 
therefore due to CatD (for details see chapter 2). The decrease of activity can thus be assigned 
to CatE. For a schematic representation of the assay, see Figure 2 of chapter 2. 
1.1.2.4 Inhibitors 
The most widely used and potent inhibitor of CatE is pepstatin A (PepA). Additionally, a wide 
variety of synthetic peptidomimetic inhibitors has been described that mediate potent CatE 
inhibition [72, 73]. However, none of these small molecule inhibitors discriminates clearly 
between cathepsin D and E. A specific inhibitor for CatE, the Ascaris pepsin inhibitor, which 
has no activity against cathepsin D, has been described [26], but is not readily available in 
quantities sufficient for functional studies because of difficulties in purification. Furthermore, 
the recombinant inhibitor may have a slightly different inhibitory profile [74].  
Although pepstatin A is not specific towards CatE or CatD, it is widely used in cell-based 
studies aimed at understanding the function of these enzymes; using cells from CatD-deficient 
mice allows pepstatin to specifically target CatE. However, another limitation of PepA for cell-
based studies is that it is inefficiently transported across the cell membrane [75]. To address 
this problem mannose-pepstatin conjugates were recently developed as targeted inhibitors of 
antigen processing [12, 75]. These mannosylated conjugates showed higher solubility than 
pepstatin in water and were efficiently incorporated into the cells via receptor-mediated uptake. 
This approach is obviously limited to cells carrying mannose receptors.  
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Our group has synthesized new cell permeable aspartic protease inhibitors that are not specific 
for any particular cell type. To achieve this, the most frequently employed cell penetrating 
peptide, namely pAntp(43-58) (penetratin), Tat(49-60), and 9-mer of L-arginine (R9), were 
synthesized. Pepstatin A was then coupled to these peptides. We found that the bioconjugate 
PepA-penetratin (PepA-P) was the most efficient cell-permeable aspartic protease inhibitor (for 
details see chapter 3) [76].  
1.1.3 Structural chemistry  
The crystal structure of CatE has not been solved so far. It is known that the amino terminal 
portion contains a Cys residue at position 43, which is responsible for disulphide bond 
formation between the two identical subunits [77]. The homodimeric form is easily converted 
into a monomeric form exhibiting full catalytic activity under reducing conditions [60, 78]. 
Additionally, as mentioned above, a highly conserved tripeptide sequence DTG is found in 
CatE from all species except rabbit [59-62]. Based on available information on CatE and the 
crystal structures of other aspartic proteases, Kuo-Chen Chou has predicted a three dimensional 
structure of CatE [79]. Ostermann et al have crystallized and solved the structure of an 
activation intermediate of CatE [80]. They reported that the overall structure resembles 
intermediate 2 in the proposed activation pathway of aspartic proteases like pepsin C and 
cathepsin D [80]. The pro-sequence is cleaved from the protease and remains stably attached to 
the mature enzyme by forming the outermost sixth strand of the interdomain β-sheet. 
Furthermore, the pro-sequence remains attached to the mature enzyme and the primed binding 
site is in a closed conformation [80]. 
1.1.4 Regulation of gene expression 
Cathepsin E has a limited tissue distribution. It is apparent that there must be a mechanism that 
regulates the transcription of the gene encoding CatE so that expression is facilitated only in 
certain types of cells. The promoter region flanking the procathepsin E gene from human [81] 
and mouse [61] do not contain a TATA box. Instead, both sequences contain an initiator 
element [61, 81] which offers an alternative binding site for TFIID (transcription factor IID) to 
initiate gene transcription [82]. Cook et al have reported that regulation of human and mouse 
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procathepsin E gene expression is not influenced by CpG methylation [83]. Furthermore, 
transcription of the CatE gene is dependent on the balance between the effects produced by 
positive-acting tissue-specific transcription factors such as GATA1 and PU1 and the negative 
influence of the ubiquitous factor YY1 [83].  
Additionally, it is also known that CatE transcription is negatively regulated by CIITA (Class II 
transactivator), a non-DNA-binding transcription factor [84]. The significance of regulation of 
CatE gene expression by this transcription factor will be discussed later in this chapter. 
1.1.5 Processing, maturation and intracellular trafficking of cathepsin E 
Like many other aspartic proteases, CatE is synthesized as a zymogen which is catalytically 
inactive towards its natural substrates at neutral pH and which auto-activates in an acidic 
environment to generate the mature enzyme via an intermediate. The processing events of pro-
cathepsin E include the removal of propeptide, glycosylation and formation of a disulphide 
bond between two cysteine residues at the NH2-terminal region to yield a homodimer. CatE is 
synthesized as a 46 kDa precursor and is later converted into the 42 kDa mature form. In this 
section, we will discuss the molecular basis of processing and intracellular trafficking of CatE. 
1.1.5.1 Role of propeptide in processing and maturation 
CatE is synthesized as an inactive precursor and is activated by proteolytic removal of N-
terminal propeptide; the process is triggered by acidic pH. The unique structural characteristics 
of propeptide are conserved in all species [59, 60, 85, 86]. The propeptide is composed of 40 
amino acid residues and is highly positively charged. Therefore, it is hypothesized that the 
propeptide is bound to active CatE mainly through electrostatic interactions. 
It has been reported that the propeptide of CatE plays an important role in the correct folding, 
maturation and targeting of this protein to its final destination [87]. Tsukuba et al. have 
constructed CatE mutants lacking the propeptide (Leu23-Phe58). They reported that this mutant 
protein was neither processed not matured and was found mostly in the ER, in comparison to 
the wild type which was mainly located in endosomes [88]. 
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1.1.5.2 Significance of catalytic activity of CatE for its acid-dependent auto-activation 
Procathepsin E is readily auto-activated upon brief incubation at an acidic pH and transforms to 
the mature form. The active site residues (Asp98, Asp283, and Thr284) are critical for 
catalysis, as mentioned before in this review [63]. Tsukuba et al published that, active site 
mutants of CatE, in which one or both aspartic acid residues were substituted with alanine, not 
only lacked catalytic activity, but were also unable to mature, thus remain stably as a 46 kDa 
precursor [88]. This indicates that catalytic activity is essential for the processing and 
maturation of this enzyme. 
1.1.5.3 ER-retention sequence in maturation and intracellular targeting of cathepsin E 
Finley and Kornfeld reported that amino acids 1-48 of mature cathepsin E are important for its 
retention in the ER [89]. Tsukuba et al constructed a mutant lacking most of this putative ER-
retention sequence, which was not converted into a mature form of the enzyme, was rapidly 
degraded in the cells and could not be detected in the endosomes [88]. This indicates that the 
putative ER-retention sequence is required for correct folding, processing, maturation and 
targeting of CatE to endosomes. 
1.1.5.4 Role of N-glycosylation of CatE in processing, maturation and intracellular 
targeting 
CatE is known to be N-glycosylated with high-mannose and/or complex oligosaccharides in the 
native state. In APC such as microglia and macrophages, the mature form of CatE is localized 
in endosomal compartments and is N-glycosylated mainly with complex-type oligosaccharides 
[34]. CatE from erythrocyte membranes (human and rat) [58] and thymocytes (rat) [90] is also 
N-glycosylated with complex-type oligosaccharides, while the enzyme from the spleen (rat) 
[59] and stomach (rat) [91] has high mannose-type oligosaccharides. This is interesting in view 
of the fact that CatE shows different subcellular localization in different cell types, as discussed 
previously in this review, and it has been suggested that the nature of its oligosaccharide chains 
may be cell-specific or may vary with its cellular localization.  
Yasuda et al constructed an N-glycosylation mutant (by changing the N residue to Q and D at 
position 73 and 305 in potential glycosylation sites of rat CatE) [92]. It was found that this 
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mutant was less stable to temperature and pH than glycosylated CatE, although its catalytic 
properties were equivalent to wild type. Tsukuba et al reported that N-glycosylation mutants 
were stably retained in cells but were not processed to the mature form and were exclusively 
confined to the ER [88]. Hence, N-glycosylation of CatE seems to play an important role in 
processing, maturation and trafficking of CatE to its final destination, but might not be essential 
for correct folding of the enzyme.  
1.1.6 Physiological roles of cathepsin E 
1.1.6.1 Pathological conditions developing in CatE-deficient mice 
CatE-deficient mice are found to develop atopic dermatitis-like skin lesions [43]. It was 
reported that they also show an increased susceptibility to bacterial infection associated with 
decreased expression of multiple cell surface Toll-like receptors [44]. According to a recent 
study [45], CatE deficiency induces a novel form of lysosomal storage disorder characterized 
by accumulation of lysosomal membrane sialoglycoproteins and the elevation of lysosomal pH 
in macrophages.  
1.1.6.2 Pathological conditions in which over-expression of CatE is observed 
CatE is expressed in pancreatic ductal adenocarcinoma [77], and its presence in pancreatic juice 
may be a diagnostic marker for this cancer [93]. Increased levels of CatE in neurons and glial 
cells of aged rats are suggested to be related to neuronal degeneration and reactivation of glial 
cells during the normal aging process of the brain [94]. 
1.1.6.3 Potential role in the MHC class II pathway 
Several lines of evidence suggest that cathepsin E plays a role in antigen processing via the 
MHC class II pathway. CatE is detectable in APC such as Langerhans and interdigitating 
dendritic cells [53] and its expression is up-regulated on activation of human B cells and B cell 
lines [35]. Moreover, a peptide derived from CatE was found to be associated with HLA-DR 
molecules in human EBV-transformed B cells [95], suggesting that it is found at the site of 
assembly of peptides and MHC class II complexes. 
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On the basis of studies utilizing specific inhibitors and cathepsin-deficient mice, CatE has been 
implicated in antigen processing. The first study to report involvement of cathepsin E in 
antigen processing was carried out by Bennett et al [13]. This study made use of a CatE-
specific Ascaris inhibitor and demonstrated that CatE is essential for processing of ovalbumin 
by murine B cells, whereas, presentation of synthetic OVA-derived peptides corresponding to 
the epitope was not affected by the specific CatE inhibitor. Similar results were obtained when 
the role of CatE in antigen presentation by microglia [56] and dendritic cells [12] derived from 
CatD-deficient mice was examined. CatE was found to be involved in processing of ovalbumin 
but not in the presentation of OVA-derived peptides. 
An immunological role for CatE in microglia was further supported by the observation that its 
expression at the RNA level is enhanced after treatment with IFN-γ while expression of CatD, 
CatB, CatL and CatS remains constant [56]. Microglia also show strong pepstatin A-sensitive 
antigen presenting ability for both, native OVA and OVA-peptides only after IFN-γ treatment. 
Because IFN-γ enhances only CatE expression, it can be suggested that CatE plays a major role 
in antigen processing. IFN-γ-activated peripheral macrophages also showed similar results [56]. 
The association of CatE expression and activity with IFN-γ treatment in microglia indicates the 
involvement of CatE in the MHC class II pathway, because IFN-γ is known to induce MHC 
class II expression as well as co-stimulatory molecules required for T-helper cell activation [96, 
97]. Moreover, in microglia and dendritic cells, CatE is present in the early endosomes and 
partially in lysosomes while CatD has purely lysosomal localization [12, 56]. This indicates 
that localization of CatE is far more appropriate for processing of exogenous antigens than 
CatD, because exogenous antigens are first processed in early endosomes after endocytosis.  
An interesting report by Yee et al [84] provided the first link between immune-specific 
regulation and Ag-processing by CatE. They observed that CatE expression is negatively 
regulated by the MHC class II transactivator (CIITA), a non-DNA-binding transcription factor 
which activates and is required for the expression of MHC II and other genes related to antigen 
presentation [98, 99]. CIITA is known to modulate immune responses also by repressing the 
transcription of other genes including IL4 [100], collagen α2 [101] and Fas ligand [102]. It was 
reported that CIITA-deficient murine and human B cells express higher amounts of CatE than 
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wild-type B cells, whereas cells overexpressing CIITA showed decreased CatE mRNA, protein 
and proteolytic activity [84]. This negative regulation of CatE expression by CIITA was very 
specific towards CatE and did not affect CatD. This regulation of CatE by CIITA might either 
inhibit or promote Ag-processing and presentation. If the latter, then production of antigenic 
epitopes by CatE could be down-regulated as part of an activation-induced shift from Ag-
processing to Ag-presentation [84]. Alternatively, it is possible that CatE cleaves productive 
antigens, such as Ag-MHC complexes or chaperones, and therefore it is down-regulated by 
CIITA. This explanation is supported by the fact that CatE cleaves human α2-macroglubulin, a 
capture protein that promotes internalization and degradation of target proteins [103]. 
Most of the above-mentioned reports point towards the involvement of CatE in antigen 
processing but not in the presentation of the synthesized antigenic peptides [12, 13, 56]. Thus, 
the general conclusion from these findings is that inhibition of CatE does not alter the number 
of MHC molecules at the cell surface which are able to bind processed peptides, and that 
inhibition of CatE might also have no effect on invariant chain processing because if the Ii 
processing is blocked, loading of MHC molecules with processed peptides is also blocked 
[104]. 
However, there are several discrepant reports showing that aspartic protease inhibitors 
effectively prevent the processing of the invariant chain [105]. CatE could be involved in the 
initial cleavage of the invariant chain, in which an unidentified endosomal aspartic protease has 
been implicated [105, 106]. Although CatE is absent from the classical late endosomal class II 
loading compartments [12], which contain cathepsin S, and in which invariant chain processing 
is thought to take place, it is possible that the invariant chain traffics transiently via an early 
endosomal compartment en route to the class II-loading pathway.  
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1.2 Overview of cathepsin D 
Cathepsin D (CatD, EC 3.4.23.5) is an intracellular aspartic protease of the pepsin superfamily. 
CatD is found in almost all mammalian cells and has a typical lysosomal localization [29, 30]. 
Early isolations of cathepsin D showed various different forms which differed in size, number 
of associated polypeptides and iso-electric point but, had similar activities [107]. Later on, site-
directed covalent modifications demonstrated that CatD had a similar active centre as pepsin, 
confirming its identity as an aspartic protease [108, 109]. It was hypothesized that the two-
chain forms were derived from the single polypeptide forms by proteolysis [110]. This is 
confirmed by the determination of N-terminal sequences of different forms of pig CatD  [111].  
Isolation of a cDNA clone [112] and of the gene [113], detailed studies of its biosynthesis 
[114], activation [115], substrate specificity [116] and determination of crystal structure [117, 
118] makes cathepsin D one of the best studied lysosomal proteinases (reviewed in [119]). 
1.2.1 Activity and specificity 
1.2.1.1 Active Sites 
Cathepsin D contains highly conserved active site residues (DTG) for the aspartic protease 
family located at residues 97-99 and 295-297 for human cathepsin D [79].  
1.2.1.2 Specificity 
Cathepsin D prefers aromatic amino acids at P1 and P1´ positions [20]. At P1, leucine is 
strongly favoured, at P2 and P1´ hydrophobic requirements are less strict [27]. A charged 
preferably basic residue is found mostly at P2´and P5´positions; at least 1 basic residue appears 
to be required by CatD at either position [27].  
1.2.1.3 Assays 
Conventional assays for measuring aspartic protease activity in biological samples employs 
acid-denatured bovine hemoglobin as substrate [52, 66, 67] . The most common assays for 
measuring aspartic protease activity and our new approach for distinguishing CatE and CatD 
activity are described in section 1.1.2.3 and chapter 2 of this thesis.  
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1.2.1.4 Inhibitors 
Cathepsin D is inhibited potently by pepstatin A. Synthetic peptides containing statine 
derivatives inhibit CatD to varying degrees but none of them has a Ki values as low as PepA 
[72, 120]. Several compounds screened for inhibition of HIV-1 protease also inhibit CatD 
[121]. Apart from that some non-peptide inhibitors have been identified, but they are also not 
as potent as PepA [122]. The specificity of these for CatD and other related aspartic proteases 
has not been carefully examined and is an important area for future work. 
The limitations of using PepA in different studies and the efforts to overcome these limitations, 
by us and other groups have been discussed in section 1.1.2.4 and chapter 3 of this thesis.  
1.2.2  Structural chemistry 
1.2.2.1 Primary structure and proteolytic processing  
Human CatD is synthesized as a precursor comprising 412 amino acids [112] and is termed as 
“preprocathepsin D”. The precursor contains an N-terminal secretion signal peptide which is 20 
residues in human [123] and is cleaved during translocation across the membrane to generate 
an inactive procathepsin D. The procathepsin undergoes autocatalytic cleavage and eventually 
become mature double-chain form. The mature form is made up of N-terminal light chain of 14 
kDa and C-terminal heavy chain of 34 kDa linked by non-covalent interactions [124].  
Cathepsin D is a glycoprotein with two N-linked oligosaccharides, one each in the light and 
heavy chains. These oligosaccharides are normally modified by phosphorylation of sixth 
position of mannose during biosynthesis [125]. Glycosylation is not necessary for folding [126] 
or enzyme activity [127] but is required for targeting of the enzyme [127]. The multiplicity of 
CatD isoforms purified from tissue extracts can be explained by proteolytic processing and 
carbohydrate modifications which produce molecules of differing isoelectric points [119].  
1.2.2.2 Crystal structure 
Baldwin et al described crystal structure of human liver cathepsin D at 2.5Å resolution [117] 
and Metcalf et al reported the structure of human spleen CatD at 3.0 Å resolution [118]. These 
structures are in general agreement with each other and previous computationally derived 
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models of CatD based on the structures of other aspartic proteases [128]. Metcalf et al reported 
that two related 170 residue domains (mostly β sheet) lie on either side of the deep 30 Å long 
active site cleft [118]. Each domain contributes an active site aspartate at the centre of the cleft 
and each contains a single carbohydrate group and two disulphide bonds. The lysosomal 
targeting region of cathepsin D defined by previous expression studies [129] is located in well 
defined electron density on the surface of the molecules. This region includes the putative 
binding site of the cis-Golgi phosphotransferase which is responsible for the initial sorting step 
for soluble proteins destined for lysosomes by phosphorylating the carbohydrates on these 
molecules [118]. Carbohydrate density is visible at both expected positions on the cathepsin D 
molecules and, at the best defined position, four sugar residues extend towards the lysosomal 
targeting region [118]. 
1.2.3 Regulation of gene expression  
Eukaryotic gene expression is controlled by both, proximal and distal elements, generally 
located in the 5` upstream region of the gene [130]. Many class II gene promoters contain a 
TATA box, which binds to the transcription factor IID and thus define the transcription 
initiation site for that gene. Genes having such promoters are termed as facultative or regulated 
genes. In contrast the promoter region of the house keeping genes lack a recognizable TATA 
box but contain multiple GC boxes which are putative binding sites for transcription factors 
Sp1 [131].  The promoter of cathepsin D has a mixed structure and it shows both of these 
features. Transcription of CatD is initiated at five major transcription sites (TSSI to –V) 
spanning 52 base pairs [132]. It has been shown that in human breast cancer cell lines, 
estrogens stimulate transcription of CatD [133]. The promoter of CatD directs two types of 
transcription initiations; TATA-dependent transcription starting about 28 bp downstream from 
the TATA box and TATA-independent transcription initiating at the other initiation sites 
upstream of the TATA box possibly directed by GC boxes and SP1 factor as in many 
housekeeping genes [132]. Estrogens stimulate TATA-dependent transcription and therefore 
not only increase transcription but also affect the pattern of initiation, with TATA-dependent 
transcription predominating.  Therefore, in stimulated conditions, CatD mRNAs preferentially 
have short 5`-untranslated sequences, whereas in basal conditions where TATA-independent 
Overview of Cathepsin D 
 
21  
 
 
transcription is dominant, the proportion of longer CatD mRNAs is increased.  Since the CatD 
gene is controlled by a mixed promoter this gene has the advantage of being both constitutively 
expressed from TATA-independent start sites and overexpressed in some physiological 
conditions such as development or tissue modeling [132].   
1.2.4 Processing, maturation and intracellular trafficking of CatD 
 Cathepsin D is synthesized on the rough endoplasmic reticulum as a pre-pro-enzyme that 
undergoes several proteolytic steps during biosynthesis to produce the mature form. Following 
initial co-translational removal of the signal peptide to generate the inactive pro-enzyme, sugars 
are attached at two N-linked glycosylation sites and the pro-enzyme is transported to Golgi 
apparatus. This 52 kDa pro-CatD is tagged for mannose-6-phospahate (M-6-P) receptors and is 
targeted to lysosomes. In lysosomal compartments, the peptide backbone of human pro-CatD 
undergoes a two-step maturation process: in the first step the pro-piece of 44 amino acids is 
removed to yield an active intermediate 48 kDa single-chain molecule. In the second step, this 
intermediate is further processed to generate double-chain mature form (reviewed in [119]). In 
this section these posttranslational modification and processing events and the factors affecting 
these events are discussed. 
1.2.4.1 Role of glycosylation in intracellular trafficking of CatD 
Normal cellular life of CatD is characterized by a special feature i.e. its strict localization 
within acidic lysosomal compartments. Transport of Pro-CatD from Golgi complex to 
downstream acidic compartments is mainly mediated by receptors specific for mannose-6-
phosphate [134] groups and also by interaction of Pro-CatD with prosaposin or other unknown 
molecules [135].  
Since glycosylation is essential in M-6-P pathway, N-linked oligosaccharides play an important 
role in the biosynthesis of pro-CatD. The two N-linked oligosaccharides (one each in the light 
and heavy chain) of CatD are normally modified by phosphorylation of sixth position of 
mannoses during biosynthesis [125]. CatD sequences from different species show substantial 
amino acid sequence identity, including conservation of the N-linked glycosylation site at 
residue 70 (human CatD numbering [112]). Human procathepsin D carries two N-linked 
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glycosylation sites at asparagine residues 70 and 199, widely separated on the surface of the 
folded protein.  Fortenberry et al [126] created monoglycosylated procathepsin D molecules by 
site-directed mutagenesis of the individual glycosylation sites. The expressed proteins were 
stable, targeted to the lysosome, and partially secreted into the medium. But the mutant in 
which both glycosylation sites were eliminated the expressed proteins were stable but most 
were not secreted and targeted poorly to the lysosome [126] . 
1.2.4.2 Role of CatD-propeptide in lysosomal sorting of CatD 
Conner [136] studied the function of the propeptide of procathepsin D in sorting to the 
lysosome using a cathepsin D deletion mutant lacking the propeptide, and using a chimeric 
cDNA encoding the cathepsin D propeptide fused to the secretory protein alpha-lactalbumin. 
The deletion mutant was glycosylated but was rapidly degraded and did not acquire an active 
conformation. Thus, the propeptide appeared to be necessary for correct folding. The chimeric 
protein was glycosylated and secreted. The coincidence of complex oligosaccharide 
modification and secretion of the chimeric protein suggested that it was slowly released from 
the endoplasmic reticulum and rapidly passed through the cell to the extracellular compartment. 
This indicates that the propeptide is necessary for folding of cathepsin D but, was not sufficient 
to direct a secretory protein to the lysosomes. In a more recent study by Yasuda etal [87] it was 
reported that propeptide for CatD is essential for the correct folding, activation and delivery of 
the protein in lysosomes  
1.2.4.3 Role of catalytic activity and auto-activation of CatD in its maturation 
Once segregated into the lysosomal compartments, the pro-CatD undergoes several proteolytic 
processing events [119]. The general mechanism proposed for the processing and activation of 
the 52 kDa pro-CatD was a combination of partial auto-activation generating a 51 kDa pseudo-
CatD which is followed by proteolytic cleavage by a lysosomal cysteine or aspartic protease 
generating a 48 kDa intermediate and finally a double-chain mature species [138]. In a recent 
study, it has been shown that cellular CatD is processed in a manner independent of its catalytic 
function and that auto-activation is not a required step [138]. Moreover, it is reported that 
Overview of Cathepsin D 
 
23  
 
 
cysteine proteases are required for the maturation of CatD, specifically the enzymes cathepsin 
B and L are shown to be involved in the process [138].   
1.2.4.4 Putative β-structure on the surface of Pro-CatD: Role in proteolytic maturation of 
CatD 
The final processing step of CatD from single to two-chain form has also been extensively 
studied. Comparison of primary structure of CatD with other aspartic proteases demonstrates an 
insertion in the region that is cleaved to generate a two-chain form [119]. The two-chain 
enzyme lacks a short segment of the insertion that is excised following cleavage. Molecular 
modeling of this region suggests that it forms a putative β-structure (β-hairpin loop) on the 
surface of human pro-CatD and thus would be disposed to proteolysis in the lysosomes where 
the cleavage occurs [139]. Yonezawa et al have identified this sequence in the stretch 
P159CQSASSASAL169 and suggested that seven (i.e. S162ASSASA168) of these 11 residues are 
removed during single to two-chain maturation process [139].  
Previously this region was suggested to play a role in stabilization and targeting of the single-
chain CatD to the processing compartments [139, 140]. The deletion of this region forming β-
hairpin loop impaired the formation of the double-chain CatD and substantially affected the 
stability of the protein [141]. Therefore, it was not possible to study its folding and targeting to 
lysosomes. However, in a recent study by Follo et al a new approach was used to mutagenize 
the region of the amino acids comprising the β-hairpin loop [124]. These new mutants were 
unable to be converted into the two-chain form but they do not compromise the folding and 
stability of the protein. These mutants reach the lysosomes and are stable as single-chain 
polypeptide. Moreover, they bear high-mannose type sugars, bind to pepstatin and are 
enzymatically active [124]. Thus, in contrast to previous reports, this new study indicated that 
the mutagenesis of this proteolytic processing region did not affect the stability or the folding 
and enzymatic activity of CatD despite the structural impairment of single to double-chain 
processing [124]. Furthermore it shows that the processing loop does not contain signals for 
lysosomal targeting as suggested previously [139, 141]. 
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1.2.5 Physiological roles of cathepsin D 
1.2.5.1 Pathological conditions developing in CatD-deficient mice 
CatD-deficient mice have been shown to develop pathological conditions like massive 
intestinal necrosis [38], thromboembolia [38], lymphopenia [38], and neuronal ceroid 
lipofuscinosis [39]. 
1.2.5.2 Pathological conditions in which over-expression of CatD is observed 
Cathepsin D is found in elevated levels in many types of cancers such as breast cancer [41], 
prostrate cancer [40] and ovarian cancer [42]. The prognostic value remains controversial.  
1.2.5.3 Potential role in the MHC class II pathway 
Cathepsin D is the major aspartic protease of the lysosomal compartment. Several studies have 
demonstrated the ability of cathepsin D to release T cell epitopes from protein antigens [11, 15, 
142, 143] and some have reported the association of cathepsin D with MHC class II antigen 
presentation [11, 144, 145].  
CatD generates antigenic peptides from ovalbumin (OVA) [11], hen egg lysozyme [143], and 
sperm whale myoglobin [142]. It is involved in processing and presentation of human serum 
albumin by murine peritoneal macrophages and veiled cells [145]. According to one study 
[144], CatD is necessary for the processing of ovalbumin. Additionally, it is localized to the 
multivesicular endosomes known as MIIC or CIIV [146, 147] that indicates the role of the 
enzyme in both antigen and invariant chain processing.  
In contrast, some reports stated that CatD may not be that important in antigen processing. 
Deussing et al [148] analyzed the ability of splenocytes from CatD-deficient mice to present 
various antigens to murine T cell hybridomas. They reported that the absence of CatD did not 
impair the presentation of epitopes from ovalbumin, hen egg lysozyme, myelin basic protein 
and pigeon cytochrome C [148]. Nishioku et al [56] reported that microglia prepared from 
cathepsin D-deficient mice retained the ability to present ovalbumin-derived antigenic peptides.  
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A more recent report from Chain et al [12] also demonstrated ovalbumin processing and 
presentation in dendritic cells derived from CatD-deficient mice. They have also observed that 
CatD deficiency does not affect antigen processing or presentation ability of the cells. 
An important limitation of all these studies mentioned above indicating that, CatD is not 
involved in antigen presentation, is that it was not clear whether or not the antigens tested were 
the substrates for CatD. In a recent study by Moss et al [149], this issue was taken into 
consideration and the involvement of CatD in processing and presentation of the model antigen 
myoglobin was tested. In vitro digestions of myoglobin with lysosomal fractions isolated from 
antigen presenting cells (APCs) showed that myoglobin is digested into a set of discrete 
products by aspartic proteases [142, 149, 150]. Moreover, myoglobin-specific T cell 
hybridomas are stimulated by CatD-digested myoglobin, but not by untreated protein, 
suggesting that CatD plays a role in myoglobin processing [149]. 
But in dendritic cells, derived from CatD-deficient mice presentation of two different 
myoglobin T cell epitopes is enhanced rather than hindered [149]. This contradiction in results 
can be explained by the finding that myoglobin processing activity persists in lysosomes of 
CatD-deficient dendritic cells.  Thus, this interesting report [149] suggested that a low level of 
aspartic protease activity is required for processing of myoglobin, but a higher level of activity 
becomes destructive. 
Deussing et al [148] reported that presentation of some antigens was enhanced in splenocytes 
lacking CatD. Similarly, Chain et al [12] noticed that DCs from CatD-deficient mice 
occasionally showed a slight increase in ovalbumin processing. Several explanations can be 
given to elucidate this effect of aspartic protease concentration on antigen presentation. For 
example, as suggested by Moss et al [149], it might reflect relative preferability for cleavage 
sites within myoglobin. At low protease concentration only the most proteolytically-susceptible 
sites, which appear to lie outside the T cell epitopes, will be cleaved [149]. At higher protease 
concentrations, less-favoured sites might also be targeted, and if these sites are present within T 
cell epitopes, antigen presentation might be impaired. This explanation was favoured by the 
fact that CatE and CatD cleavage sites were observed in A3 epitope (102-118) [149].  
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Secondly, it is also observed that MHCII may preferentially capture large processed antigen 
fragments [151]. Thus higher levels of protease activity may generate antigenic peptides with a 
less favourable size [149]. Some of the studies discussed earlier in this chapter have also 
implied that aspartic proteases in general are not involved in antigen presentation as pepstatin A 
has not affected presentation of processed peptides [13, 56], whereas antigen processing was 
pepstatin A-sensitive. 
Chain et al [12] reported that  DCs derived from CatD-deficient mice were capable of antigen 
processing as well as presentation. Furthermore, it has also been reported that microglia 
isolated from CatD-deficient mice retained ability for antigen presentation [56]. Consistently, 
some other studies that utilized peripheral APCs derived from CatD-deficient mice indicated 
that CatD is not involved in degradation of invariant chain [148, 152]. Riese et al also 
described that cathepsin S, but not cathepsin B or D, is necessary for the digestion of Ii from 
MHC II molecules [153].  
However, there are several discrepant reports showing that aspartic protease inhibitors 
effectively prevented the processing of invariant chain [14, 105, 154]. According to one study 
[144], CatD is necessary for degradation of Ii from the MHC class II alpha beta heterodimer in 
endosomes in order to express functional MHC class II molecules, that will then bind to 
antigenic peptides. Zhang et al [14] has reported that CatD is involved in degradation of 
invariant chain in ovalbumin-immunized mice. 
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1.3 Aims of the thesis 
The present work aims to contribute to the understanding of differences in biochemical 
characteristics of cathepsin E and D and their possible functional role in MHC II pathway. 
More specifically, the project intended to develop and characterize new tools for studying these 
proteases that are very similar in their enzymatic characteristics. 
The specific aims were as follows 
• Synthesis and characterization of monospecific antibodies for cathepsin E. 
• To develop an assay for distinct measurement of cathepsin E and D and utilization of 
this assay in measuring the activity of these enzymes in endosomal and lysosomal 
fractions of different antigen presenting cells. 
• To improve the accessibility of pepstatin A (PepA, highly potent aspartic protease 
inhibitor) to antigen processing compartments by conjugating it with well-known cell 
penetrating peptides (CPPs). Once the cell-penetrating ability of different PepA-CPP 
conjugates is evaluated, exploitation of these conjugates in antigen presentation assays. 
• To study the proteolytic activity of cathepsin E at different pH values, as distinct 
cleavage specificities of CatE at neutral and acidic pH have been reported in some 
previous studies. 
• To study in detail the substrate specificity of cathepsin E and D and selection of the 
specific substrate for either enzyme. Utilization of these substrates in monitoring the 
activity of CatE and CatD in different biological samples. 
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2 A new approach for distinguishing cathepsin E 
and D activity in antigen processing organelles 
                                   A related manuscript has been published in  
                                    The FEBS Journal, 125 [3], 392-399 (2007) 
 
 
2.1 Abstract  
Cathepsin E (CatE) and D (CatD) are the major aspartic proteinases in the endolysosomal 
pathway. These proteinases exhibit similar specificity and therefore it is difficult to distinguish 
between them since known substrates are not exclusively specific for one proteinase. Here, a 
substrate-based assay is presented, which is highly relevant for immunological investigations 
since it detects both, CatE and CatD in antigen-processing organelles. Therefore it could be 
used to study the involvement of these proteinases in protein degradation and the processing of 
invariant chain. An assay combining a new monospecific CatE antibody and the substrate Mca-
Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [where Mca is (7-
methoxycoumarin-4-yl)acetyl and Dnp is dinitrophenyl] is presented. This substrate is digested 
by both proteinases and therefore can be used to detect the total aspartic proteinase activity 
(TAPA) in biological samples. After depletion of CatE by immunoprecipitation, the remaining 
activity is due to CatD and the decrease of activity can be assigned to CatE. The activity of 
CatE and CatD in cytosolic, endosomal and lysosomal fractions of B cells, dendritic cells and 
Chapter 2. A new approach for distinguishing cathepsin E and D activity in antigen processing organelles 
 
 
 
30 
human keratinocytes was determined. Our data clearly indicate that CatE activity is mainly 
located in endosomal and that of CatD in lysosomal compartments. Hence, this assay can also 
be used for characterization of subcellular fractions using CatE as an endosomal marker, 
whereas CatD is a well-known lysosomal marker. Moreover, the highest TAPA (total aspartic 
protease activity) was detected in dendritic cells and the lowest in B cells. The presented assay 
exhibits a lower detection limit compared to common antibody-based methods without lacking 
specificity. 
2.2 Introduction  
Cathepsin E and D are the major intracellular aspartic proteinases. They have similar enzymatic 
properties, e.g. susceptibility to various proteinase inhibitors such as pepstatin A and similar 
substrate preferences as both prefer bulky hydrophobic amino acids at P1 and P1` positions 
[155]. Additionally, both enzymes have approximately the same acidic pH optimum towards 
various protein substrates such as hemoglobin [57, 67]. 
However, these enzymes have different tissue distribution and cellular localization suggesting 
that both enzymes might have more specific physiological functions. CatE is a non-lysosomal 
proteinase with a limited distribution in certain cell types, including gastric epithelial cells [33], 
but mainly present in cells of the immune system, such as macrophages [29], lymphocytes [29], 
microglia [34] and dendritic cells [12]. It is reported to be localized in different cellular 
compartments, such as plasma membranes [36], endosomal structures [34], endoplasmic 
reticulum and Golgi apparatus [30, 34, 37]. In contrast, CatD is a typical lysosomal enzyme 
widely distributed in almost all mammalian cells [29-32]. 
Recent studies with CatE- and CatD-deficient mice have provided an additional evidence of the 
association of these enzymes with different physiological effects. CatD-deficient mice 
developed massive intestinal necrosis [38], thromboembolia [38], lymphopenia [38], and 
neuronal ceroid lipofuscinosis [39]. Cathepsin E-deficient mice are found to develop atopic 
dermatitis-like skin lesions [43]. It was reported recently that CatE-deficient mice show an 
increased susceptibility to bacterial infection associated with decreased expression of multiple 
cell surface Toll-like receptors [44]. According to a most recent study [45], CatE deficiency 
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induces a novel form of lysosomal storage disorder showing the accumulation of lysosomal 
membrane sialoglycoproteins and the elevation of lysosomal pH in macrophages.  
CatD has also been suggested to play a role in determining the metastatic potential of several 
types of cancer; high levels of CatD have been found in prostate [40], breast [41] and ovarian 
cancer [42]. CatE is expressed in pancreatic ductal adenocarcinoma [77], and its presence in 
pancreatic juice is reported to be a diagnostic marker for this cancer [93]. Increased levels of 
CatE in neurons and glial cells of aged rats are suggested to be related to neuronal degeneration 
and reactivation of glial cells during the normal aging process of the brain [94]. 
CatE and CatD are found to play an important role in the MHC class II pathway. CatD is 
reported to be involved in processing of MHC II-associated invariant chain [14], in antigen 
processing and presentation [15, 145]. CatE is also reported to be involved in antigen 
processing by B cells [13, 35] microglia [56] and murine dendritic cells [12]. 
Several studies have been conducted to determine the subcellular localization of CatE and CatD 
in different cell types, but there are few reports regarding the activity of these enzymes in 
antigen processing-relevant organelles [29, 156]. Previous reports have described highly 
selective substrates for aspartic proteinases, but none of the described substrates is exclusively 
specific for CatE or CatD [19, 20, 156]. In most of the studies additional methods or inhibitors 
are used to measure the specific activity of CatE or CatD. For example, to determine the CatD 
activity specifically, a CatD digest and pull-down assay was described [156]. Other studies 
have utilized a specific inhibitor for CatE, the Ascaris pepsin inhibitor, which inhibits pepsins 
and CatE [26], but does not affect other types of aspartic proteinases including CatD [19, 157]. 
This inhibitor was originally isolated from the round worm Ascaris lumbricoides [25]. 
However, it is not commercially available. 
In the present study, CatE and CatD activity was determined in subcellular fractions 
(lysosomal, endosomal and cytosolic) of antigen-presenting cells. For measuring TAPA (total 
aspartic proteinase activity) in biological samples, the previously described peptide substrate 
Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [19] was used which is 
digested by both, CatE and CatD. It is an intramolecularly-quenched fluorogenic peptide 
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derivative in which the fluorescent signal of the fluorophore Mca is quenched by the 
chromophoric residue Dnp. After cleavage of the peptide, the quenching efficiency is decreased 
resulting in an increase in fluorescence. The activity determined in subcellular fractions was 
completely inhibited by pepstatin A. Therefore, this activity can be only attributed to aspartic 
proteinases and represents TAPA. For the specific determination of CatE and CatD activity, 
CatE was specifically depleted by immunoprecipitation. The remaining activity is due to CatD, 
and the decrease of activity is assigned to CatE. This approach allows the specific and highly 
sensitive measurement of both, CatE and CatD activities in biological samples. 
 
2.3 Experimental procedures 
2.3.1  Enzymes and chemicals 
CatD (bovine kidney) was purchased from Calbiochem (Darmstadt, Germany) and stored as a 
300 U/ml stock solution in 0.1 M citrate buffer, pH 4.5, at -20 °C. CatE was purchased from 
R&D systems (Wiesbaden, Germany) and stored as a 0.1 mg/ml stock solution in 50 mM 
citrate buffer, pH 6.5, containing 150 mM NaCl at -20 °C. Pepstatin A (Calbiochem) was 
dissolved in methanol. Activated CH Sepharose 4B was purchased from Amersham 
Biosciences (Munich, Germany). The substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-
Lys(Dnp)-D-Arg-NH2 [19] was obtained from Bachem (Weil am Rhein, Germany). 
2.3.2  Generation and immobilization of a monospecific CatE antibody 
The antigenic peptide SRFQPSQSSTYSQPG (CatE 118-132) was selected from the protein 
sequence using the laser gene software (DNASTAR, Madison, WI) and controlled for 
specificity to CatD. It was synthesized as a single peptide and as a  multiple peptide antigen 
(MAP) peptide (SRFQPSQSSTYSQPG)8-[70]4-(Lys)2-Lys-Gly-OH using standard Fmoc/tBu 
[158] chemistry on a multiple peptide synthesizer Syro II (MultiSynTech, Witten, Germany). 
The peptides were purified using RP-HPLC and the identity was confirmed using ESI-MS. 
Peptide purities were determined via analytical RP-HPLC and proved to be higher than 90%. 
The single peptide was coupled to keyhole limpet hemocycanin (KLH) using the 
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glutardialdehyde method. The antiserum was obtained after repeated immunization of a rabbit 
with a 1:1 mixture of the peptide-KLH-conjugate and the MAP. This antiserum was purified by 
affinity chromatography on a CH-activated Sepharose 4B column (Amersham Biosciences) 
containing the peptide immobilized via a stable peptide bond. Peptide immobilization was 
performed as described by the manufacturer. The antiserum was applied on the column at 
0.5ml/min and recycled overnight. The column was washed with 20 column volumes of PBS 
(Gibco). Elution was performed with 10 volumes of 0.1M glycine/HCl (pH 2.5). Antibody-
containing fractions were immediately neutralized with 1M Tris/HCl (pH 8.5) and then 
concentrated on a 20 kD membrane. The resulting antibody was retested by ELISA and showed 
the expected specificity to the peptide epitopes and the CatE protein, but a complete negative 
reaction against CatD. The purified monospecific antibody was immobilized on CH-activated 
sepharose as described by the manufacturer. After coupling for 3 hours at room temperature, 
the gel was deactivated with 0.1M Tris-HCl, pH 8.0, for 2 hours at room temperature. To block 
any remaining active sites, the material was further incubated with 5% bovine serum albumin 
for additional 2 hours. After washing with PBS, the immobilized antibody was stored in PBS 
containing 0.02% (w/v) NaN3 at 4°C. 
2.3.3  ELISA 
The wells of microtiter plates (Nunc Brand Products, MaxiSorb surface, Wiesbaden, Germany) 
were coated with CatE (10ng), CatD (10ng) or the peptide SRFQPSQSSTYSQPG (1ng) in PBS 
in a final volume of 100 µl/well at 4°C overnight. The plates were washed three times with 200 
µl of washing buffer (PBS/0.05% Tween 20, pH 7.0) and blocked with blocking buffer 
(PBS/0.05% Tween 20, pH 7.0, containing 2% BSA) for 2 hr at 37°C. After washing, the plates 
were treated for 1 h at 37°C with our monospecific CatE antibody (diluted in PBS/0.05% 
Tween 20, pH 7.0, containing 0.5% BSA) or commercial CatD antibody. After washing, the 
plates were incubated with HRP-conjugated goat anti-rabbit Ig (Dianova, Hamburg, Germany; 
1:5000 diluted in PBS/0.05% Tween 20/0.5% BSA). 100 µl/well of ABTS (azinodiethyl-
benzthiazoline-sulfonate)/H2O2 in substrate buffer (citrate buffer 100mM, pH 4.5) was added 
and the colour development analyzed at a wavelength of 405 nm. 
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For competitive inhibition ELISA, the antiserum was pre-incubated with different 
concentrations of CatE or CatD (40 min, room temperature) and then used as primary 
antibodies for standard ELISA for detecting the antigenic peptide SRFQPSQSSTYSQPG 
(0.1µg/well). 
2.3.4  Cell culture 
The EBV-transformed human B cell line WT100 and the immortalized human keratinocyte cell 
line HaCaT were cultured in RPMI 1640 medium (Gibco Life Technologies, Paisly, United 
Kingdom) supplemented with 10 % (v/v) heat-inactivated fetal calf serum (FCS, Gibco), 
penicillin (final concentration: 100 U/ml, Gibco) and streptomycin (final concentration: 0.1 
mg/ml, Gibco) at 37 °C in tissue culture flasks (Nunc, Wiesbaden, Germany). 
PBMC (peripheral blood mononuclear cells) were isolated by Ficoll/Paque (PAA Laboratories 
Pasching Austria) density gradient centrifugation of heparinized blood obtained from buffy 
coats. Isolated PBMC were plated (1x 108 cells/8 ml/ flask) into 75 cm2 Cellstar tissue culture 
flasks (Greiner Bio-One GmbH, Frickenhausen, Germany) in RPMI 1640 (Gibco Life 
Technologies) under the same culture conditions as for WT100 and HaCaT. After 1.5 hour of 
incubation at 37°C, non-adherent cells were removed and adherent cells were cultured in 
complete culture medium supplemented with GM-CSF (Leukomax; Sandoz, Basel, 
Switzerland) and IL-4 (R&D systems) for six days as described previously [159]. This resulted 
in a cell population consisting of approximately 70% DCs (data not shown) as determined by 
flow cytometry (BD FACSCalibur, Heidelberg, Germany). 
2.3.5 Determination of mRNA expression levels for CatE using RT-PCR 
RNA was extracted from DCs, WT100 and HaCaT cells using the TRIazol reagent as described 
by the manufacturer (Invitrogen, Karlsruhe, Germany). Reverse transcription of 2 µg total RNA 
was initialized by 200 U of Superscript II reverse transcriptase (Invitrogen), 4 µl synthesis 
buffer (5-fold concentrated, Invitrogen), 2.5 µl random primers (10 mM, Promega, Mannheim, 
Germany), 1 µl dithiothreitol (100 mM, Invitrogen), 1 µl dNTP mix (10 mM, Promega) and 0.5 
µl rRNAsin (Promega) in a final volume of 20 µl. After incubation at room temperature for 10 
min, the reaction mixtures were set to 42 °C for 1 h. Then amplification was carried out adding 
Experimental procedures 
 
 
35  
 
 
5 µl generated cDNA to 45 µl reaction mixture (11.0 % (v/v) 10-fold PCR buffer (Roche, 
Basel, Switzerland), 3.3 % (v/v) of both primers (5’-CATGATGGAATTACGTT-3’ and 
5’GAATGATCCAGGTACAGCAT-3’) 10 µM each (Operon Technologies Alameda, 
California, USA), 2.2 % (v/v) dNTP mix (10 mM, Promega) in molecular grade water and 1.1 
% (v/v) Taq DNA polymerase (Roche) and running 35 cycles each for 35 sec at 94 °C, 30 sec 
at 50 °C and 60 sec at 72 °C. Single PCR amplicons were analysed using agarose gel 
electrophoresis. 
2.3.6 Subcellular fractionation and Western blot analysis 
Cell fractionation was performed as previously described by Schroter et al [160]. Briefly, 4×107 
- 8×107 cells were harvested, resuspended in 1.5 ml fractionation buffer, (10 mM Tris buffer, 
250 mM sucrose, pH 6.8), and then homogenized using a cell cracker (HGM Lab Equipments, 
Heidelberg, Germany). Then debris was separated by centrifugation at 8000 xg for 10 min. 
Mitochondria and the endolysosomal fractions were separated by ultra-centrifugation at 
100,000 xg for 5 min (Beckman TL100 ultracentrifuge, Palo Alto, USA). Finally, lysosomes 
were separated from endosomes by hypotonic lysis with ddH2O (approx. 2.5-fold of the pellet 
volume for keratinocytes and DCs, and 5-fold of the pellet volume for B cells) and 
centrifugation at 100,000 xg for 5 min. Lysosomal material was released in the supernatant, 
endosomes remained in the pellet. Total protein content was determined according to Bradford 
[161]. For schematic representation of the protocol see Figure 1. 
Subcellular fractions were separated by SDS-polyacrylamide gel electrophoresis (50 µg total 
protein per lane) on a 12 % separating gel and transferred to a PVDF-membrane (Amersham 
Biosciences, Freiburg, Germany). Membranes were then blocked for 1 h using TBST (0.15 M 
NaCl, 10 mM Tris, 0.05 % (v/v) Tween 20, pH 8.0) containing 10 % (v/v) Roti® Block (Roth, 
Karlsruhe, Germany). Rabbit anti-human CatD antibody (Calbiochem) was diluted 1:5000 and 
rabbit anti-human CatE antibody was diluted 1:2000. Western blots were developed according 
to the ECL protocol of Amersham Biosciences. 
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Figure 1: Schematic representation of subcellular fractionation. 
 
2.3.7 Detection of NAG (N-acetyl-β-D-glucosaminidase) activity 
NAG activity was measured as described by Schmid et al [162]. Briefly, 1µg protein from each 
fraction was added to 100 µL of 0.1M citrate buffer, pH 5, containing 0.8 mM 4-
methylumbelliferyl-N-acetyl-β-D-glucosaminide (Sigma, Deisenhofen Germany) and 0.1% 
Triton X-100. Fluorescence (λex = 360 nm, λem. = 465 nm) was measured every 5 min at 37° 
C using a fluorescence reader (Tecan Spectra Fluor, Crailsheim, Germany). NAG activity was 
determined by linear regression using a minimum of seven measurement points. 
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2.3.8 Parallel detection of CatE and CatD activity 
TAPA (total aspartic proteinase activity) and specific catalytic activities of CatE and CatD 
were determined fluorometrically by hydrolysis of the substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-
Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2. Appropriate amounts of CatE, CatD or subcellular 
fraction (20µg of total protein) were added to 80µl digestion buffer (50mM sodium acetate 
buffer pH 4.0) and the reaction was started by addition of 1µl substrate solution (stock solution 
2mM in DMSO). Progress of fluorescent product formation was recorded using a fluorescence 
reader (Tecan Spectra Fluor) on kinetic mode at 37°C (λex =340, λem = 405). Activities were 
determined by linear regression analysis using a minimum of five measurement points. All the 
experiments were done in triplicates yielding TAPA i.e. CatE and CatD activity. Aspartic 
proteinase activity could be completely inhibited using 1 µl of a 1 mM pepstatin A solution in 
methanol (1 µl methanol showed no inhibitory effect). 
For the specific determination of CatE activity samples were subjected to immunoprecipitation 
of CatE prior to the above described assay. 20 µg of total protein from each subcellular fraction 
was incubated with 20µl of monospecific CatE antibody immobilized on a CH-activated 
sepharose at 4°C overnight. 
In this way, the measured increase in fluorescence intensity is exclusively caused by CatD. The 
difference between total aspartic proteinase and CatD activity can be assigned to CatE activity. 
For schematic representation of the assay see Figure 2. 
2.3.9 Analytical RP-HPLC 
1 µl of the fluorogenic peptide substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-
Lys(Dnp)-D-Arg-NH2 (1 mM in DMSO) was incubated at 37 °C in 80 µl digestion buffer (50 
mM sodium acetate buffer, pH 4.0) containing the appropriate amount of CatE, CatD or a 
subcellular fraction (with or without pepstatin A treatment or after immunoprecipitation (IP) of 
CatE). The reaction was terminated by boiling the samples for 5 min at 98°C. 5µl of the 
reaction mixture was separated by analytical RP-HPLC using a C8 column (150 × 2 mm, 
Reprosil 100, Dr. Maisch GmbH, Tuebingen, Germany) with the following solvent systems: 
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(A) 0.055 % (v/v) TFA in water and (B) 0.05 % (v/v) TFA in 80 % (v/v) ACN in water. Elution 
was performed using a linear gradient from 5 % to 80 % B within 35 min. Fluorescence 
detection was carried out at λem.= 350 and λex = 450 . Appropriate fractions were collected and 
analysed by MALDI-MS. 
2.3.1 MALDI-MS 
0.5 µl of each RP-HPLC fraction was mixed with 0.5 µl DHB-matrix (10 mg/ml (w/v) 2,5-
dihydroxybenzoic acid in 60 % (v/v) ethanol containing 0.1 % (v/v) TFA) and applied on a 
gold target for MALDI-MS using a MALDI time-of-flight system (Reflex IV, serial number: 
26159.00007, Bruker Daltonics, Bremen, Germany). Signals were generated by accumulating 
120 – 210 laser shots. Raw data were analyzed using the software Flex Analysis 2.4 (Bruker 
Daltonics). 
 
Figure 2. Schematic representation of assay to distinguish between CatE and D activity. (A) 
TAPA (total aspartic proteinase activity) was measured by hydrolysis of fluorogenic substrate 
Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2. (B) The observed activity 
was pepstatin A (PepA) sensitive hence was only due to aspartic proteases. (C) Samples were 
subjected to immunoprecipitation (IP) using our monospecific antibody before above described 
assay. Now increase in fluorescence intensity is exclusively caused by CatD. The difference 
between total aspartic proteinase and CatD activity can be assigned to CatE activity.
Results and Discussion 
 
39  
 
 
2.4 Results and Discussion  
2.4.1  Expression of cathepsin E mRNA in different cell lines 
To determine the expression of CatE at the mRNA level in different cell lines, RT-PCR was 
performed using RNA extracted from DCs (monocyte derived human dendritic cells), WT100 
(EBV-transformed B-cell line) and HaCaT (immortalized human keratinocyte cell line). PCR 
products from the cell lines were analyzed by gel electrophoresis and found to contain a band 
of the expected size (241bp) (Figure 3.). As these cell lines were found to be positive for CatE 
mRNA they were used for the determination of enzymatic activity of CatE and CatD. Previous 
studies have also shown that murine dendritic cells [12] as well as another EBV-transformed B-
cell line (Fc7) are positive for CatE mRNA [35].  
  
Figure. 3. CatE expression at mRNA level in different cell lines. Total RNA was extracted 
from HaCaT, WT100 and DCs. Equal amounts of total RNA (2µg) from each sample were used 
for RT-PCR. After reverse transcription, specific primers for human CatE were used to amplify 
CatE cDNA.  
 
2.4.2  Determination of antibody specificity 
The monospecific antibody for cathepsin E was raised against the antigenic peptide 
SRFQPSQSSTYSQPG (CatE 118-132). This peptide was selected from the CatE sequence 
using laser gene software (DNASTAR, Madison, WI) for antigenicity and surface probability 
(Figure 4A). BLAST tool analysis showed that the selected peptide sequence does not exhibit 
significant homology with sequences in cathepsin D or any other known protein therefore it is 
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specifically present in cathepsin E. Figure 4B. shows sequence alignment of cathepsin E and 
cathepsin D. 
 
Figure. 4A. Prediction of antigenic peptides for generation of monospecific antibody against 
cathepsin E. Amino acid sequence of CatE was obtained from National Center for 
Biotechnology Information Protein database and subjected to analysis of secondary structure, 
hydrophilicity profile, and antigenicity using the program Protean of DNAStar software 
(DNAStar, Inc., Madison, WI). The polypeptide composed of 15 amino acids 
SRFQPSQSSTYSQPG (CatE 118-132) was selected as an antigenic peptide for raising CatE 
antibodies. 
 
Results and Discussion 
 
41  
 
 
The antiserum obtained was further purified by affinity chromatography on CH-activated 
sepharose containing the peptide SRFQPSQSSTYSQPG immobilized via stable peptide bonds. 
The results of indirect ELISA (Figure 4C) showed that the antibody specifically recognized 
CatE and the antigenic peptide SRFQPSQSSTYSQPG used to generate the antibody and gave a 
complete negative reaction towards CatD.  
To determine the specificity and cross reactivity of resulting CatE antibody, indirect ELISA, 
competitive inhibition ELISA (CI-ELISA) and Western blot analysis were performed.  
CI-ELISA was performed to further enhance the specificity of the antibody. The antibody was 
pre-incubated with different concentrations of CatE and CatD before performing the standard 
ELISA for detecting the antigenic peptide SRFQPSQSSTYSQPG. Pre-incubation of cathepsin 
E with the antibody exhibited a dose-dependant inhibition of antibody binding (IC50 value: 48.6 
ng; Figure. 4D). Increasing concentration of cathepsin D did not affect antibody binding. This 
experiment shows that CatE specifically binds to the monospecific antibody in a free system. 
Western Blot analysis also confirms that the monospecific antibody specifically recognizes 
CatE and not CatD (data no shown). 
 
Figure 4B. Sequence alignment of cathepsin E and cathepsin D. The alignment was 
performed using conventional BLAST search engine. Only the small region of CatE containing 
the sequence SRFQPSQSSTYSQPG (antigenic peptide, CatE 118-132, which was used for 
generating monospecific antibodies) was included during the BLAST operation (sequence is 
seen underlined in the figure). This peptide was selected from the CatE sequence using laser 
gene software (DNASTAR, Madison, WI) for antigenicity and surface probability. BLAST tool 
analysis showed that the selected peptide sequence does not exhibit significant homology with 
sequences in cathepsin D or any other known protein, therefore it is specifically present in 
cathepsin E.  
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Figure 4C. Determination of specificity of monospecific antibody (raised against 
SRFQPSQSSTYSQPG) by indirect ELISA. The purified monospecific antibody specifically 
recognized CatE (10ng) and the antigenic peptide (SRFQPSQSSTYSQPG), and gave a 
complete negative reaction towards same amount of CatD (10ng). Values are means ± 
standard deviations, n = 3 (Insertion: 10 ng of CatE and CatD, and 1ng of antigenic peptide 
were incubated on ELISA plate, CatE and CatD antibodies were used for the detection at 
dilutions of 1:10000 and 1:5000  ). 
Figure 4D. Competitive Inhibition of antibody (raised against SRFQPSQSSTYSQPG) 
binding to SRFQPSQSSTYSQPG-coated plates by CatE. Immunoplates were coated with 
antigenic peptide SRFQPSQSSTYSQPG (0.1µg/well). Monospesific antibodies were pre-
incubated with different concentrations of CatE or CatD, before standard ELISA. ELISA was 
performed as described in material and methods. The increasing concentration of cathepsin E 
caused inhibition of antibody binding giving the IC50 value of 48.6 ng. Whereas, the same 
concentrations of CatD had no effect on antibody binding. Data points are means ± standard 
deviations, n = 2 
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2.4.3 Characterization of subcellular fractions 
To control the quality of subcellular fractions, N-acetyl-β-D-glucosaminidase (NAG) activity 
was determined, since it is a wide-spread and well-established marker for endosomal/lysosomal 
compartments [162]. Table 1 shows the activity of NAG in subcellular fractions of different 
cell lines. As expected, all cell lines showed highest NAG activity in lysosomal fractions (LFs) 
and lower in endosomal fractions (EFs). Cytosolic fractions (CFs) had very low NAG activity. 
 
Table 1. NAG activity in subcellular fractions (fluorescence /min /µg protein) of different 
cell lines. Activities were determined by linear regression analysis taking at least seven 
measurement points. Values depicted are means ± SD (n = 3) 
 
Cell line Subcellular fraction NAG activity (fluorescence /min/µg protein) 
Cytosolic (CF) 0.5 ± 0.05 
Lysosomal (LF) 15.2 ± 0.3 HaCaT 
Endosomal (EF) 7.0 ± 0.37 
Cytosolic (CF) 0.4 ± 0.02 
Lysosomal (LF) 9.6 ± 0.1 WT100 
Endosomal (EF) 2.2 ± 0.07 
Cytosolic (CF) 0.7 ± 0.07 
Lysosomal (LF) 25.2 ± 0.07 DCs 
Endosomal (EF) 8.0 ± 0.2 
 
 
2.4.4 Western blot analysis of subcellular fractions from different cell lines used 
for CatE and CatD determination 
For immunochemical determination of subcellular localization of CatE and CatD, Western blot 
analysis was performed. No CatE was recovered from any subcellular fraction of WT100. 
Endosomal fraction of DCs and HaCaT contained a significant larger amount of CatE than the 
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respective lysosomal fractions, but no CatE was found in the cytosolic fractions of any of the 
cell lines (Figure 5.). As expected, higher amounts of CatD were detectable in lysosomal 
fractions. No CatD was detected by Western blotting in the cytosolic fraction of any of the 
three cell types (Figure 5.).  
 
 
Figure 5. CatE and CatD expression at protein level in antigen processing relevant organelles 
of different cell lines. Equal amounts of total protein (50 µg) from each sample were applied for 
SDS-PAGE followed by Western blot analysis. Representative immunoblots with the 
monospecific CatE antibody and reprobe of the same blot with the CatD antibody are shown. (C; 
Cytosolic fraction, L; Lysosomal fraction, E; Endosomal Fraction). 
 
2.4.5 Specific inhibition of CatE by immunoprecipitation 
In order to determine the specificity of our immobilized CatE antibody in depleting CatE from 
the samples, it was tested with CatE and CatD. CatE (recombinant) was completely 
immunoprecipitated by the antibody against Cat E (Figure 6A), whereas it had almost no effect 
on CatD activity (Figure 6B.). This approach for depleting proteinase activity from complex 
biological samples is flexible and can be used for other proteinases as well. 
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A                                                                                 B 
Figure 6. Effect of immunoprecipitation (IP) of CatE and pepstatin A treatment on (A) CatE 
and (B) CatD activities. (A) (■) Hydrolysis of the fluorogenic peptide substrate Mca-Gly-Lys-
Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 (1µM) by 10 ng of CatE in 50mM sodium 
acetate buffer (pH 4) at 37°C. (▲) Incubation with pepstatin A for 15 min at 37°C prior to 
hydrolysis inhibited the activity of CatE completely. (●) Immunoprecipitation (IP) of CatE 
prior to hydrolysis reaction also completely inhibited the activity of CatE. (B) (■) Hydrolysis of 
the fluorogenic peptide substrate (1µM) by 10 ng of CatD in 50mM sodium acetate buffer (pH 
4) at 37°C. (▲) Incubation with pepstatin (1µM) A for 15 min at 37°C prior to hydrolysis 
reaction inhibited the activity of CatD completely (●) IP of CatE prior to hydrolysis has no 
effect on CatD activity, hence IP was specific towards CatE only. 
 
2.4.6 Activity of Cat E and CatD in subcellular fractions of different cell types 
The activity of CatE and CatD was determined in subcellular fractions of different cell types 
using a combination of the peptide substrate, aspartic proteinase inhibitor (pepstatin A) and 
depletion of CatE by immunoprecipitation. Activities were determined by linear regression 
using a minimum of five measurement points as described in Materials and Methods. The 
activity in all subcellular fractions of these different cell types was completely inhibited when 
the samples were pre-incubated with pepstatin A (TAPA). 
For differential measurements of CatE and CatD activity, samples were subjected to IP 
(immunoprecipitation) of CatE. The decrease in activity after IP is attributed to CatE and the 
remaining activity is assigned to CatD. As expected, the highest CatD activity was determined 
for lysosomal fractions of all the three cell types tested [156]. In contrast, CatE activity was 
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mainly detected in endosomal fractions as indicated in Table 2 and Figure 7 A-C. A low level 
of CatD activity was determined for endosomal fractions of all three cell types. In HaCaT and 
DCs a low level of CatE activity was found in lysosomal fractions. In the EBV-transformed B 
cell line (WT 100) an almost equal level of CatE and CatD activity was found in the lysosomal 
fraction, most likely due to overlapping subcellular fractions. Cytosolic fractions of all three 
cell types showed very low CatE activity, but no CatD activity. Moreover, the overall activity 
in subcellular fractions of the three cell types tested varied substantially, as did CatE and CatD 
activity. DCs showed highest while WT100 showed lowest overall activity.  
As shown in Table 2, endosomal fractions (EFs) of HaCaT showed about 5.5fold larger CatE 
activity as compared to the corresponding fractions of WT100, whereas DCs (EFs) showed 
around 19 times larger CatE activity than WT100 (EFs). Table 2 also demonstrates that 
lysosomal fractions (LFs) of HaCaT had 7.2 times higher CatD activity than LFs of WT100 and 
LFs from DCs had around 16.6 times higher CatD activity than LFs of WT100. 
2.4.7 Analysis of peptide fragments obtained by digestion of the fluorogenic 
substrate with subcellular fractions, CatE or CatD, using RP-HPLC and 
MALDI-MS 
To further confirm that the activity measured in subcellular fractions by the fluorescence assay 
was only due to aspartic proteinases, the peptide substrate was digested by CatE, CatD or 
subcellular fractions (as described in Experimental Procedures). The peptide fragments thus 
generated were separated by RP-HPLC using fluorescence detection (λex =350, λem = 450) and 
identified by MALDI-MS. This method allowed detection of only N-terminal fragments 
containing the fluorophore Mca. 
Figure 8A shows the chromatogram of the undigested peptide substrate Mca-Gly-Lys-Pro-Ile-
Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 as a negative control. The fluorescence signal is 
quenched due to resonance energy transfer between the fluorophore and the quencher group. 
Figure 8B depicts the results of digestion of the substrate with CatE, leading to only one 
cleavage product, because only the Phe-Phe bond is susceptible to cleavage by CatE or CatD 
[19]. The peak with a retention time of 25.54 min corresponds to fragment Mca-Gly-Lys-Pro-
Results and Discussion 
 
47  
 
 
Ile-Leu-Phe as analyzed by mass spectrometry (Table 3). Figure 8C shows digestion of the 
substrate with CatD giving a profile similar to that of CatE, i.e. only one peak is visible with 
the same retention time. However, when digested with the lysosomal fraction (Figure. 8E.) of 
HaCaT, an additional peak with the retention time of 22.87 min was observed. Digestion of 
substrate with the endosomal fraction (Figure. 8F.) of HaCaT gave similar RP-HPLC-profile 
as the lysosomal fraction. 
Digestion of the substrate with LF (lysosomal fraction) and EF (Endosomal fraction) (Figure. 
8H. and I.) was completely inhibited by pepstatin A confirming that the activity observed in 
our assay was solely due to aspartic proteinases. The additional peak observed after digestion 
of substrate with LF and EF (Figure 8E and F) was a C-terminal truncated peptide (Mca-Gly-
Lys-Pro-Ile-Leu) as analyzed by MALDI-MS (Table 3). This carboxypeptidase activity can 
only occur after aspartic proteinases have created cleavage products, as the undigested substrate 
contains a protecting D-Arg residue at the C-terminus. 
Substrate digestion by the lysosomal fraction (Figure 8K) after IP of CatE had almost no effect 
on the RP-HPLC profile. This indicates that the activity observed in LF was mainly due to 
CatD. Digestion by the endosomal fraction (Figure 8L) was inhibited after IP of CatE 
indicating that the activity in the endosomal fraction was primarily CatE activity. The cytosolic 
fraction (CF) had not indicated any cleavage; hence no activity of CatE and CatD was observed 
by RP-HPLC. This coincides with the results from the fluorescence assay by which only very 
low level activity in CF was determined. Digestion of substrate with subcellular fractions of 
DCs and WT100 also gave similar profiles in RP-HPLC (data not shown). 
In conclusion, the combination of methods described here facilitates the specific and parallel 
measurement of CatE and CatD activity in antigen-processing organelles. The data clearly 
show that our approach for detection of CatE and CatD is more sensitive than immunodetection 
by Western blot analysis. It allows detection of CatE activity in subcellular fractions of WT100, 
compared to Western blot analysis, where CatE was not detectable. With this assay it was also 
possible to discriminate between CatD activity in endosomal and lysosomal fractions, whereas 
the difference between the amounts of CatD in these fractions was not significant when 
detected by Western blot. 
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Theses experimental conditions are also more specific compared to previously described 
assays, because specificity of detection was not only based on the peptide sequence but was 
markedly increased by the use of monospecific antibody, utilized for depletion of CatE. This 
type of assay is flexible and can be used for discriminating activity of other proteinases with 
similar enzymatic properties. 
This approach distinguishes between the activities of enzymatically similar proteinases CatE 
and CatD and therefore can be used in studies aimed at understanding the involvement these 
enzymes in antigen processing and presentation. 
 
Table 2. CatE and CatD activity in subcellular fractions (pmol Mca liberated / min / 20 µg of 
total protein) of different cell lines. Activities were determined by linear regression analysis 
taking at least five measurement points. Values depicted are means ± SD (DCs, n = 2; HaCaT 
and WT100, n = 3, where n is the number of individual experiments performed).  
 
Cell line Activity Cytosolic fraction    
pmol Mca liberated/min 
Lysosomal fraction  
pmol Mca liberated /min 
Endosomal fraction 
pmol Mca liberated/min 
TAPAa 13.4 ± 2.15 106.3 ± 6.94 82.0 ± 11.33 
Cat E 13.4 ± 2.15 25.3 ± 14.01 65.4 ± 11.22 HaCaT 
Cat D n.db 80.9 ± 12 16.6 ± 8.40 
TAPAa 0.49 ± 0.19 20.9 ± 1.99 13.7 ± 0.69 
Cat E 0.49 ± 0.19 9.5 ± 0.54 11.8 ± 1.23 WT100 
Cat D n.db 11.3 ± 2.54 1.9 ± 0.77 
TAPAa 0.76 ± 0.24 210.7 ± 18.40 232.8 ± 49.65 
Cat E 0.76 ± 0.24 23.2 ± 20.54 225.7 ± 50.38 DCs 
Cat D n.db 187.5 ± 2.19 7.1 ± 0.72 
 
a
 TAPA; total aspartic proteinase activity     b Not detectable  
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Figure 7. Distribution of TAPA (total aspartic protease activity), CatE and CatD activity in 
subcellular fractions of (A) HaCaT. (B) WT100. (C) DCs. Equal amounts of total protein (20 
µg) were used for the determination of CatE and CatD activities, determined by linear 
regression analysis using a minimum of five measurement points. Values depicted are means ± 
SD (DCs, n = 2; HaCaT and WT100, n = 3, where n is the number of individual experiments). 
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Fig 8. RP-HPLC profiles of peptide fragments obtained after digestion of the substrate with 
CatE, CatD or subcellular fractions of HaCaT. Fluorogenic peptide substrate Mca-Gly-Lys-
Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 (10µM) was incubated at 37°C in 
digestion buffer (50 mM sodium acetate buffer, pH 4.0) containing CatE (10 ng), CatD (10 ng) 
or subcellular fraction (20µg)  (A) Undigested fluorogenic substrate Mca-Gly-Lys-Pro-Ile-Leu-
Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2. (B) Substrate digested with CatE (C) CatD (D) CF 
(Cytosolic fraction) (E) LF (Lysosomal fraction) (F) EF (Endosomal fraction) (G) CF after 
PepA treatment (H) LF after PepA treatment (I) EF after PepA treatment (J) CF after IP of 
CatE (K) LF after IP of CatE (L) EF after IP of CatE. 
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Table 3. Identified peptides after digestion of fluorogenic peptide substrate by CatE, CatD 
and subcellular fractions of HaCaT as determined by MALDI-MS.  
Retention times allude to those in figure 8. 
Sample Digestion products 
Retention 
time 
(min) 
Expected 
mass 
[M+H]+ 
[M+H]+ ∆Da 
CatE 
 
Mca-GLPILF-OH 
 
25.54 890.80 890.77 0.03 
CatD 
 
Mca-GLPILF-OH 
 
 
25.19 890.80 891.76 0.96 
Lysosomal 
fraction 
 
Mca-GLPILF-OH 
 
Mca-GLPIL-OH 
 
25.90 
 
22.87 
 
890.80 
 
743.70 
 
890.90 
 
743.70 
 
0.1 
 
0.0 
Endosomal 
fraction 
 
Mca-GLPILF-OH 
 
Mca-GLPIL-OH 
 
 
25.44 
 
22.38 
 
890.80 
 
743.70 
 
890.80 
 
743.80 
 
0.0 
 
0.1 
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3 
3 A novel cell penetrating aspartic protease inhibitor 
blocks processing and presentation of tetanus toxoid 
more efficiently than pepstatin A 
                         A related manuscript has been published in 
Biochem Biophys Res Commun..(2007), 14;364(2):243-9 
 
 
3.1 Abstract 
Selective inhibition of enzymes involved in antigen processing such as cathepsin E and 
cathepsin D is a valuable tool for investigating the roles of these enzymes in the processing 
pathway. However, the aspartic protease inhibitors, including the highly potent pepstatin A 
(PepA), are inefficiently transported across the cell membrane and thus have limited access to 
antigen processing compartments. Previously described mannose-pepstatin conjugates were 
efficiently taken up by the cells via receptor mediated uptake. However, cells without mannose 
receptors are unable to take up these conjugates efficiently. The aim of the present study was to 
synthesize new cell permeable aspartic protease inhibitors by conjugating pepstatin A with 
well-known cell penetrating peptides (CPPs). To achieve this, the most frequently used CPPs 
namely pAntp(43-58) (penetratin), Tat(49-60), and the 9-mer of L-arginine (R9), were 
synthesized followed by coupling pepstatin A to the peptides. The enzyme inhibition properties 
of these bioconjugates and their cellular uptake into MCF7 (human breast cancer cell line), 
Boleths (EBV-transformed B cell line) and dendritic cells (DC) was studied. We found that the 
bioconjugate PepA-penetratin (PepA-P) was the most efficient cell-permeable aspartic protease 
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inhibitor in comparison to PepA. Additionally, we found that PepA-P efficiently inhibited the 
tetanus toxoid C-fragment processing in peripheral blood mononuclear cells (PBMC), primary 
DC and in primary B cells. Therefore, PepA-P can be used in studying the role of intracellular 
aspartic proteases in the MHC class II antigen processing pathway. Moreover, inhibition of 
tetanus toxoid C-fragment processing by PepA-P clearly implicates the role of aspartic 
proteinases in antigen processing. 
 
3.2 Introduction 
Cathepsin E (CatE) and cathepsin D (CatD) are the major intracellular aspartic proteases in the 
endolysosomal pathway. The involvement of these proteases in cellular processes such as 
antigen processing and presentation is mainly demonstrated by using specific aspartic protease 
inhibitors [12, 13, 56, 105]. However, the aspartic protease inhibitors, including the highly 
potent pepstatin A (isovaleryl-L-valyl-L-valyl-4-amino-3-hydroxy-6-methylheptanoyl-L-
alanyl-4-amino-3-hydroxy-6-methylheptanoic acid) [163, 164], a peptide originally isolated 
from the filtrates of cultures of Streptomyces [165], are inefficiently transported across the cell 
membrane [75].  
In a recent study, mannose-pepstatin conjugates were used as cell-permeable aspartic protease 
inhibitors, and these inhibitors blocked ovalbumin processing in dendritic cells [12, 75]. These 
conjugates were reported to show higher solubility in water compared to pepstatin A (PepA) and 
were efficiently internalized by the cells via receptor mediated uptake. However, the cells, which 
do not carry the mannose receptors such as B cells, are not able to take up these conjugates 
efficiently [12, 75]. Therefore, the application of these inhibitors is limited to cells bearing 
mannose receptors. 
A valuable approach for intracellular delivery of macromolecules involves their conjugation to 
the cell-penetrating peptides (CPPs) [166-169]. These peptides can be internalized by most cell 
types and also have the capability of co-transporting the conjugated biomolecules both in vivo 
[170] and in vitro [171]. CPPs have been employed in the intracellular delivery of a wide range 
of biomolecules such as antigenic peptides [172], antisense oligonucleotides [173], full length 
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proteins [174, 175] or nano particles [176] and liposomes [177]. The most widely used CPPs are 
peptides from HIV-1 Tat [178, 179], antennapedia protein of Drosophila (penetratin) [180] and 
synthetic peptides such as oligo-arginine [181].   
The present study illustrates the synthesis of new cell permeable inhibitors of aspartic proteases 
that are not cell specific. The most frequently used CPPs namely, pAntp(43-58) (penetratin), 
Tat(49-60) and the 9-mer of L-arginine (R9), were synthesized on a trityl resin followed by 
coupling pepstatin A as a complete molecule to the N-terminal amino group of the peptides 
with an amide bond. The enzyme inhibition properties of these bioconjugates and their cellular 
uptake into MCF7 (human breast cancer cell line), Boleths (EBV-transformed B cell line) and 
dendritic cells was examined. We found that the bioconjugate PepA-penetratin (PepA-P) is the 
most effective cell-permeable aspartic protease inhibitor in comparison to PepA. Moreover, it 
was observed that PepA-P efficiently inhibited the tetanus toxoid processing in peripheral 
blood mononuclear cells (PBMC), primary dendritic cells (DC) and in primary B cells. 
Therefore, PepA-P can be a useful tool for studies aimed at understanding the role of 
intracellular aspartic proteases in the MHC class II antigen processing pathway in different 
antigen presenting cells. 
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3.3 Experimental procedures 
3.3.1 Enzymes and chemicals 
Cathepsin D was purchased from Calbiochem (Darmstadt, Germany) and stored as a 300 U/ml 
stock solution in 0.1 M citrate buffer, pH 4.5, at -20 °C. Cathepsin E was purchased from R&D 
systems (Wiesbaden, Germany) and stored as, 0.1 mg/ml stock solution in 25 mM MES, 0.15 M 
NaCl, pH 6.5, and 50 % glycerol, at -20 °C. Pepstatin A was purchased from Calbiochem. The 
substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [19] was obtained 
from Bachem (Weil am Rhein, Germany). 
3.3.2 Synthesis of pepstatin-CPP conjugates 
Peptide sequences are: RQIKIWFQNRRMKWKK (pAntp (43-58), Penetratin), RKKRRQ-
RRRPPQ (Tat(49-60)), RRRRRRRRR (R9). Peptides were synthesized using standard Fmoc/tBu 
chemistry [182] and synthesis was performed on the multiple peptide synthesizer Syro II 
(MultiSynTech, Witten, Germany) on a 0.025-mmol scale using a 6-fold molar excess of Fmoc 
amino acids (MultiSynTech, Witten, Germany) on TCP-resin (PepChem, Reutlingen, Germany). 
All reagents and solvents for peptide synthesis were purchased from Merck KGaA (Darmstadt, 
Germany). In situ activation was performed using TBTU (6 eq) and HOBt (1 eq) followed by the 
addition of N-methylmorpholine (12 eq) in N,N-dimethylformamide. After completion of the 
automated synthesis, the resin-bound peptides were Fmoc-deprotected using 20 % (v/v) 
piperidine in N,N-dimethylformamide twice for 15 min and washed subsequently with N,N-
dimethylformamide, isopropyl alcohol, and diethyl ether.   
Pepstatin A (25.7 mg, 0.0375 mmol) was dissolved in 1ml DMF and coupled manually to each 
resin bound peptide according to the aforementioned TBTU/NMM/HOBt procedure. Coupling 
time was 12 hrs at room temperature. The resin was washed intensively with DMF, isopropyl 
alcohol and finally with diethyl ether. To release the peptides from the resin and to remove the 
side chain protecting groups, the following solution was used: 92% (v/v) trifluoroacetic acid 
containing 3% (v/v) thioanisol, 3% (w/v) phenol, and 2% (v/v) ethanedithiol. The crude products 
were precipitated and washed twice in diethyl ether, dried, and dissolved in 80 % (v/v) tert-
butanol in water followed by lyophilisation. Crude compounds were purified using preparative 
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reversed-phase high performance liquid chromatography (RP-HPLC) and the identity of the 
conjugates was confirmed using MALDI-MS. Purity of each PepA-CPP conjugate was 
determined via analytical RP-HPLC and proved to be above 95 %.  
Only the peptides (penetratin, Tat(49-60), and R9) without PepA were also used in some 
experiments. These peptides were released from the resin directly as described above. 
3.3.3 Proteinase assay for determination of IC50 values for PepA and PepA-CPP 
conjugates against CatE and CatD  
Aspartic proteinase activity was determined fluorometrically by hydrolysis of the substrate 
Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2. CatE (10 ng) or CatD (10 
ng) were pre-incubated with various concentrations of PepA or PepA-CPP conjugates (at a 
series of twofold dilutions) in 50 mM sodium acetate buffer, pH 4.0. The reaction was started 
by addition of 1nmol substrate (stock solution: 1 mM in DMSO, 1 µl of stock solution was 
dissolved in 10 µl of the reaction buffer separately and then added to the reaction mixture). 
Progress of fluorescent product formation was recorded using a fluorescence reader (Tecan 
Spectra Fluor, Crailsheim, Germany) on kinetic mode at 37°C (λex =340, λem = 405). 
Activities were determined by linear regression analysis using a minimum of 15 measurement 
points. Inhibitory activity of PepA and its conjugates is expressed as IC50, which represents 
the concentration of the compound that inhibits 50 % of the maximal (uninhibited) enzyme 
activity.  
3.3.4 Cell culture 
PBMC (peripheral blood mononuclear cells) were isolated by Ficoll/Paque (PAA 
Laboratories Pasching Austria) density gradient centrifugation of heparinized blood obtained 
from buffy coats. Isolated PBMC were plated (1x 108 cells/8 ml/ flask) into 75 cm2  Cellstar 
tissue culture flasks (Greiner Bio-One GmbH, Frickenhausen, Germany) in RPMI 1640 
(Gibco Life Technologies), supplemented with 10 % (v/v) heat-inactivated fetal calf serum 
(FCS, Gibco), penicillin (final concentration: 100 U/ml, Gibco) and streptomycin (final 
concentration: 0.1 mg/ml, Gibco). After 1.5 hour of incubation at 37°C, non-adherent cells 
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were removed and adherent cells were cultured in complete culture medium supplemented 
with GM-CSF (Leukomax; Sandoz, Basel, Switzerland) and IL-4 (R&D systems) for six days 
as described previously [159]. This resulted in a cell population consisting of approximately 
80% DCs (data not shown) as determined by flow cytometry (BD FACSCalibur, Heidelberg, 
Germany).  
Boleths (EBV-transformed human B cell line) and MCF7 (human breast cancer cell line) were 
cultured in RPMI 1640 medium (Gibco Life Technologies, Paisly, United Kingdom) 
supplemented with 10 % (v/v) heat-inactivated fetal calf serum (FCS, Gibco), penicillin (final 
concentration: 100 U/ml, Gibco) and streptomycin (final concentration: 0.1 mg/ml, Gibco) at 
37 °C in tissue culture flasks (Nunc, Wiesbaden, Germany). 
3.3.5 Cellular uptake of PepA and PepA-CPP conjugates 
PepA and PepA-CPP conjugates were dissolved in minimal amount of methanol and diluted with 
medium to final working concentrations. Cells (MCF7, Boleths and dendritic cells) were exposed 
to 1, 3, 5 and 10 µM of each conjugate for 120 min. At the end of the incubation time the loading 
medium was removed and cells were washed with PBS. Non-internalized, surface-bound 
compounds were eliminated by trypsinization for 10 min as recommended by previous studies 
[166, 183, 184].  Cells were lysed in NP40 lysis buffer (1% NP-40, 50 mM sodium acetate, pH 
4.0).  
Aspartic proteinase activity in cell extracts was determined fluorometrically by hydrolysis of the 
substrate MOCAc-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2, as described in 
proteinase assay (3.1.3). Each experiment was conducted three times. Results are expressed as % 
relative residual activity which represents the percent of the total activity in untreated cells 
(control).
3.3.6 Cell viability assay 
MCF7, Boleths and dendritic cells were exposed to increasing concentrations of PepA and 
PepA-CPP conjugates as described above. The loading medium was removed and cells were 
washed with PBS. Non-internalized, surface-bound compounds were eliminated by 
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trypsinization for 10 min. Cells were washed with PBS and apoptosis was determined by 
flowcytometery (BD FACSCalibur) using 7-amino actinomycin D (7-AAD) (Sigma-Aldrich). 
3.3.7 T cell proliferation assay  
PBMC from healthy donors were pulsed with the corresponding tetanus toxoid C-fragment (10 
µg/ml) for four days. Then the cells were harvested and stained with CD3-PerCP, CD45RA-
PE, CD25-APC and CD134-FITC (BD Biosciences, Heidelberg, Germany). The co-expression 
of CD25 and CD134 of memory T cells (CD3+ and CD45RA-) was analysed by flowcytometry 
[185]. Additionally, the supernatants were collected and the cytokine production (IFN-γ and IL-
2) was measured using ELISA assays, following the protocols described by the company’s 
manual (R&D systems, Minneapolis, MN, USA). 
 
3.4 Results 
3.4.1  Synthesis of pepstatin derivatives 
PepA-cell penetrating peptide (PepA-CPP) conjugates, namely, PepA-Penetratin (PepA-P), 
PepA-Tat(49-60), and PepA-R9, were synthesized by solid-phase synthesis on TCP-resin using 
standard Fmoc/tBu chemistry [182]. In general, C-terminal modified pepstatin derivatives do 
not alter their inhibitory activity [186]; therefore, cell penetrating peptides were synthesized on 
a trityl resin and then pepstatin A was coupled as a whole molecule on the N-terminal amino 
group of the peptide with an amide bond. The completed conjugates were cleaved from the 
resin by the TFA cleavage mixture. Crude compounds were purified using preparative 
reversed-phase high performance liquid chromatography (RP-HPLC) and identity of the 
conjugates was confirmed using MALDI-MS. Purity of each PepA-CPP conjugate was 
determined via analytical RP-HPLC and proved to be higher than 95 %.  
The compounds were obtained without any difficulty and their characteristics are summarized 
in Table 1. PepA-Tat(49-60) and PepA-R9 were readily soluble in methanol and DMSO as 
PepA, whereas PepA-P was comparatively less soluble. 
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Table 1:   Characteristics of PepA-CPP conjugates.  
Pepstatin A- 
CPP 
conjugates 
Conjugated 
CPP 
Sequence of conjugated 
CPP 
[M+H]+  
calculated 
[M+H]+  
measured 
PepA-P pAntp(43-58); Penetratin RQIKIWFQNRRMKWKK 2914.69 2914.34 
PepA-Tat(49-60) HIV-1Tat(49-60) RKKRRQRRRPPQ 2329.91 2330.39 
PepA-R9 Oligo-
arginine ;R9 RRRRRRRRR 2091.62 2092.28 
 
3.4.2 Inhibitory effect of pepstatin A-CPP conjugates on the enzymatic activity 
of CatE and CatD  
To evaluate the usefulness of PepA-CPP conjugates as cell penetrating aspartic proteinase 
inhibitors it was important to determine whether or not the inhibitory effect of these conjugates 
was altered in comparison to PepA. Therefore, the inhibitory activity (IC50) of PepA and the 
PepA-CPP conjugates (PepA-P, PepA-Tat(49-60) and PepA-R9) against CatE and CatD was 
determined using FRET-based proteinase assay.  
In accordance to previous reports [163, 164], PepA inhibited CatE and CatD with IC50 values at 
subnanomolar concentrations (Table 2). PepA-CPP conjugates also potently inhibited CatE and 
CatD (Table 2).  Hence the attachment of the cell-penetrating peptides did not result in any 
significant reduction in the inhibitory effects of PepA 
Table 2. Inhibitory effect (IC50) of PepA and PepA-conjugates against CatE and CatD.  
Inhibitory activities were determined using FRET-based proteinase assay and expressed as 
IC50 (nM) means ± SD (N = 2, where N  is the number of experiments performed) 
. 
 
Inhibitor Cathepsin E Cathepsin D 
PepA 0.255 ± 0.12 0.21 ± 0.13 
PepA-P 0.92 ± 0.13 0.92 ± 0.21 
PepA-Tat(49-60) 0.52 ± 0.14 0.76 ± 0.21 
PepA-R9 0.47 ± 0.11 0.72 ± 0.11 
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3.4.3 Comparative evaluation of cellular uptake of pepstatin A-CPP conjugates 
To compare the cellular uptake of PepA or PepA-CPP conjugates, human dendritic cells, 
human EBV-transformed B-cell line (Boleths) and human breast cell cancer cell line (MCF7) 
were treated with various concentrations of these compounds. These different cell types were 
incubated with increasing concentration of PepA and PepA-CPP conjugates, for 120 min as 
described in experimental procedures. Following the incubation period, cells were washed 
extensively and then trypsinized for 10 min in order to remove non-internalized surface-bound 
PepA and PepA-CCP conjugates as suggested by previous studies [166, 183, 184]. The cells 
were lysed and lysates were subjected to FRET-based proteinase assay in order to measure the 
reduction in aspartic protease activity. Relative residual activity was calculated for each sample 
as a percentage of aspartic proteinase activity in cells without the treatment of inhibitors.  
As illustrated in Figures 1A-C and Table 3, a dose-dependent inhibition of aspartic proteinase 
activity was observed in MCF7 cell line after treatment with PepA and the PepA-CPP 
conjugates. PepA-P is the most effective cell penetrating inhibitor amongst all the inhibitors 
tested. At end concentration of 10 µM, PepA-P resulted in only 3.9 ± 0.3% relative residual 
activity, while at the same concentration PepA, PepA-Tat(49-60) and PepA-R9 resulted in 45.4 
± 5.5%, 29.8 ± 3.2% and 77.0 ± 5.2 % relative residual activities, respectively. The 10 µM 
concentration of PepA-P was the most effective concentration in inhibiting aspartic proteinases 
in MCF7 cell line. At higher concentrations of PepA-P, inhibition of aspartic proteases was 
lower, most likely due to the low solubility of PepA-P in aqueous solution (data not shown). 
As demonstrated in Figures 2A-C and Table 3, the EBV-transformed B cell line Boleths 
exhibited similar dose-dependent inhibition of aspartic proteinases activity. Also, for this cell 
line, PepA-P was the most potent inhibitor: 10 µM concentration of PepA-P resulted in only 
16.2 ± 1.5 % relative residual activity, whereas the same concentration of PepA and PepA-
Tat(49-60) resulted in 88.0 ± 8.1% and 59.2 ± 5.4% relative residual activities, respectively. Of 
note, 10 µM concentration of PepA-R9 showed no reduction in aspartic protease activity in 
Boleths (Fig. 2C, Table 3). 
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Dendritic cells also showed similar results; 10 µM concentration of PepA-P (Figures. 3A-C, 
Table 3) resulted in only 14.4 ± 0.5% relative residual activity, whereas, the same 
concentration of PepA, PepA-Tat(49-60) and PepA-R9 resulted in 59.8 ± 1.0%, 45.4 ± 3.1 and 
53.3 ± 2.1 relative residual activities, respectively.  
Similar concentrations of the peptides (penetratin, Tat(49-60) and R9) showed no effect on 
aspartic proteinase activity in all the three cell types tested (Figures. 1-3, Table 3). Thus, we 
found that PepA-P is the most potent cell-permeable aspartic protease inhibitor in comparison 
to PepA and the other PepA-CPP conjugates tested in the present study. 
3.4.4 Cell viability assay 
Cell viability assay was performed to determine whether or not the observed reduction in 
aspartic protease activity in different cell types after treatment with different PepA-CPP 
conjugates was due to any cytotoxic effect of the conjugates. Cell viability was determined 
flowcytometrically by 7-AAD staining. The results of two independent experiments revealed 
that PepA, PepA-Tat(49-60), PepA-P and PepA-R9 were not toxic to human EBV-transformed 
B-cell line (Boleths) and human breast cell cancer cell line (MCF7) up to the highest 
concentration (10 µM) investigated in the present study. For dendritic cells PepA-P showed a 
mild cytotoxicity (around 27%) only at a concentration of 10 µM.  
3.4.5 PepA-P reduces tetanus toxoid C-fragment (TTC) specific T cell activation 
Having established that PepA-P is the most effective cell penetrating aspartic protease inhibitor 
in comparison to PepA or other PepA-CPP conjugates tested, the ability of the inhibitor to 
affect antigen-processing was investigated. 
The effect of both PepA and PepA-P was tested in a T cell proliferation assay using primary 
human cells and the antigen tetanus toxoid C-fragment (TTC). Human peripheral mononuclear 
cells (PBMC) were isolated from healthy donors followed by the isolation of primary B cells 
(CD19+), dendritic cells (CD1c+) and untouched CD4+ T cells. Antigen presenting cells 
(APCs), i.e. PBMC, B cells and dendritic cells, were co-cultured with CD4+ T cells in the 
presence of the antigen TTC, with or without PepA-P or PepA. After four days in culture, 
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activated T cells were analyzed by flowcytometric analysis. Activated memory T cells were 
gated for their expression of CD45RA-, CD3+ and CD25+ and the activation marker CD134 as 
described previously [185]. T cell activation markers CD25 and CD134 were decreased to a 
large extent when PBMC were treated with PepA-P. In contrast, PepA treatment showed no 
difference in the co-expression of CD25 and CD134 in comparison to the experiment without 
inhibitor (Figure. 4A). Similar results were obtained when isolated B cells and dendritic cells 
were treated with PepA-P (Figures. 4B-C). The peptide penetratin alone had no effect on T cell 
activation.  
To further confirm the decreased T cell activation we investigated the cytokine profile in the 
respective culture supernatants from PBMC. We found that IFN-γ and IL-2 were decreased 
when PBMC were treated with PepA-P compared to treatment with PepA or penetratin (Fig. 
4A). Our data clearly show that the cell permeable aspartic protease inhibitor PepA-P, but not 
PepA, interfered with antigen processing of intact primary APCs resulting in inhibition of TTC-
specific memory T cell activation. 
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 Table 3:  % Relative residual activity in cell extracts from different cell lines after treatment 
with PepA-CPP conjugates. Activities were determined by FRET-based proteinase assay 
followed by linear regression analysis taking at least five measurement points. Relative 
residual activity was calculated as percentage of total activity in untreated cells. Values 
depicted are means ± SD; n = 3, where n is the number of individual experiments performed. 
 
 
 
 
% Relative residual activity in MCF7 cell line after treatment with different concentrations 
of PepA-CPP conjugates 
Inhibitor 1 µM 3 µM 5 µM 10 µM 
PepA 112.8 ± 13.5 110.5 ± 14.4 82.3 ± 10.2 45.4 ± 5.5 
Penetratin 116.5 ± 9.1 117.2 ± 16.0 119.3 ± 10.6 101.0 ± 13.8 
PepA-P 80.5 ± 3.7 29.2 ± 1.7 14.6 ± 2.2 3.9 ± 0.3 
Tat(49-60) 89.9 ± 4.1 90.0 ± 0.65 101.1 ± 4.1 88.6 ± 4.9 
PepA-Tat(49-60) 88.6 ± 4.9 77.0 ± 3.1 73.7 ± 6.7 29.8 ± 3.2 
R9 101.4 ± 3.5 97.6 ± 2.9 96.0 ± 4.2 103.4 ± 2.5 
PepA-R9 102.4 ± 3.1 89.0 ± 4.6 79.3 ± 12.2 77.0 ± 5.2 
% Relative residual activity in Boleths cell line after treatment with different 
concentrations of PepA-CPP conjugates 
Inhibitor 1 µM 3 µM 5 µM 10 µM 
PepA 104.2 ± 8.2 96.5 ± 10.7 92.9 ± 7.6 88.0 ± 8.1 
Penetratin 98.3 ± 7.0 102.4 ± 8.5 95.6 ± 7.4 103.0 ± 6.0 
PepA-P 62.8 ± 3.3 57.8 ± 4.3 34.1 ± 3.8 16.2 ± 1.5 
Tat(49-60) 99.4 ± 9.0 87.7 ± 6.9 92.5 ± 3.5 97.3 ± 7.3 
PepA-Tat(49-60) 91.3 ± 3.9 95.9 ± 0.9 73.0 ± 3.8 59.2 ± 5.4 
R9 90.7 ± 1.9 94.5 ± 8.2 87.4 ± 6.7 100.5 ± 3.2 
PepA-R9 116.5 ± 4.0 114.2 ± 3.6 111.6 ± 1.8 114.6 ± 6.6 
% Relative residual activity in Dendritic cells after treatment with different concentrations 
of PepA-CPP conjugates 
Inhibitor 1 µM 3 µM 5 µM 10 µM 
PepA 82.5 ± 0.7 79.6 ± 3.4 59.3 ± 2.7 59.4 ± 1.0 
Penetratin 94.3 ± 1.1 97.2 ± 3.3 100.0 ± 2.9 100.8 ± 3.9 
PepA-P 51.9 ± 4.7 34.8 ± 2.0 15.9 ± 1.0 14.4 ± 0.5 
Tat(49-60) 108.7 ± 6.0 112.7 ± 2.9 70.7 ± 7.1 87.4 ± 16.2 
PepA-Tat(49-60) 65.0 ± 4.6 66.3 ± 4.0 48.7 ± 1.3 45.4 ± 3.1 
R9 103.6 ± 0.2 87.2 ± 3.8  101.4 ± 2.7 100.0 ± 2.1 
PepA-R9 72.9 ± 2.9 72.4 ± 3.0 70.0 ± 1.1 53.3 ± 2.1 
Results 
 
65  
 
 
 
 
Figure 1. Dose-dependent inhibition of aspartic proteinase activity in MCF7 cell line.  MCF7 
cells were incubated with increasing concentrations of PepA(1-10 µM), different PepA-CPP 
conjugates or CPPs for 120 mins. By trypsinization non-internalized cell surface bound 
conjugates and peptides were removed. Reduction in aspartic proteinase activity in the cell 
extracts from all the samples was determined using FRET-based proteinase assay. Effect of (A) 
PepA-P (B) PepA- Tat(49-60) (C) PepA-R9 in comparison with PepA is represented as relative 
residual activity, calculated as a percentage of aspartic proteinase activity in cells without the 
treatment of inhibitors (control). The most effective cell penetrating inhibitor was PepA-P for 
MCF7 cell line. 
A
C
B
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Figure 2. Dose-dependent inhibition of aspartic proteinase activity in Boleths cell line Effect 
of (A) PepA-P (B) PepA- Tat(49-60) (C) PepA-R9 in comparison with PepA on aspartic 
proteinase activity in Boleths cell line. Aspartic proteinase activity in the cell extracts from all 
the samples was determined using FRET-based proteinase assay. For experimental conditions 
see legend to figure 1. 
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Figure 3. Dose-dependent inhibition of aspartic proteinase activity in dendritic cells. Effect of 
(A) PepA-P (B) PepA- Tat(49-60)  (C) PepA-R9 in comparison with PepA on aspartic proteinase 
activity in dendritic cells. Aspartic proteinase activity in the cell extracts from all the samples 
was determined using FRET-based proteinase assay. For experimental conditions see legend to 
figure 1. 
 
                  
A
C
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Figure 4. T cell activation was decreased when incubated with PepA-P. (A) PBMC, (B) 
magnetic beads isolated B cells (CD19+) or (C) mDC (CD1c+) were co-cultured with 
autologous T cells in the presence or absence of penetratin, PepA-P and PepA. Tetanus toxoid 
C-fragment (TTC, 5 µg/ml) was then added and cultured for five days. Activation of memory T 
cells was determined by analyzing the co-expression of CD25 and CD134 flowcytometrically. 
IL-2 and IFN-γ production were identified in the respective supernatant by ELISA. Data are 
representative of three independent experiment 
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3.5 Discussion 
Our objective was to synthesize cell-penetrating inhibitors of aspartic proteases that are not only 
specific for any particular type of cells. To achieve this the most frequently used CPPs, namely 
pAntp(43-58) (penetratin), Tat(49-60) and the 9-mer of L-arginine (R9) were synthesized followed by 
coupling pepstatin A to the peptides. We report that the bioconjugate PepA-penetratin (PepA-P) 
is the most effective cell-penetrating aspartic protease inhibitor in comparison to PepA and other 
PepA-CPP conjugates evaluated in the present study.  
The studies aimed at understanding the role of aspartic proteases in antigen processing are 
difficult to pursue mainly due to two problems. The first problem is the lack of a specific 
substrate for both, CatE and CatD. The two enzymes have similar enzymatic properties and it is 
difficult to distinguish between their activities. To address this problem we have recently 
described a new approach to differentiate between the activities of cathepsin E and cathepsin D 
in organelles relevant to antigen processing [71].  
The other major problem is the absence of an inhibitor which clearly differentiates between CatE 
and CatD. A specific inhibitor for CatE, the Ascaris pepsin inhibitor, which was reported to have 
no activity against cathepsin D, has been described [26]. However, this inhibitor is not readily 
available in sufficient quantities for functional studies because of difficulties in purification. 
Furthermore, the recombinant inhibitor may have a slightly different inhibitory profile [74]. 
In order to compensate for the absence of a specific inhibitor for CatE or CatD, in recent studies 
on the role of cathepsin E and cathepsin D in antigen processing, the tendency has been to use a 
combination of genetic deficiency (CatD-deficient mice) and different aspartic protease 
inhibitors, mainly pepstatin A.  In the cells derived from CatD-deficient mice, the aspartic 
protease inhibitors will selectively block CatE, as cathepsin E and cathepsin D are the only 
known pepstatin A-sensitive aspartic proteases that are expressed on protein level in cells of the 
immune system. However, the aspartic protease inhibitors, including the most widely used and 
highly potent pepstatin A (PepA), are inefficiently transported across the cell membrane. To 
overcome this problem Chain et al. [12] have recently described mannose derivatives of 
pepstatin that showed higher solubility in water as compared to pepstatin and were efficiently 
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taken up by the cells via receptor-mediated uptake. However, cells without mannose receptors 
can not take up these conjugates efficiently. 
Over the past decade, several cell penetrating peptides have been identified and employed in a 
number of studies for the delivery of conjugated macromolecules [166, 167, 169, 187, 188]. In 
this study we report the synthesis of pepstatin A-cell penetrating peptide (PepA-CPP) conjugates. 
The most frequently used CPPs, namely Tat(49-60), pAntp(43-58) (penetratin) and the 9-mer of L-
arginine (R9) were synthesized and then pepstatin A was coupled as a whole molecule on the N-
terminal amino group of the peptides with an amide bond. Our results indicate that the 
attachment of the cell penetrating peptides does not result in any significant reduction in the 
inhibitory effects of PepA. We have demonstrated that among PepA and the three conjugates 
(PepA-penetratin (Pep-P), PepA-Tat(49-60) and PepA-R9) synthesized and tested, PepA-P was the 
most efficient cell permeable aspartic protease inhibitor and inhibited the aspartic protease 
activity in intact human dendritic cells, human EBV-transformed B-cell line (Boleths) and 
human breast cell cancer cell line (MCF7). Furthermore, PepA-P reduced tetanus toxoid C-
fragment processing in PMBC (peripheral mononuclear blood cells), DCs (dendritic cells) and B 
cells. These results suggest that PepA-P possesses an inhibitory effect against aspartic proteases 
not only in vitro, but also after internalization into intact cells.  
Additionally, inhibition of tetanus toxoid C-fragment processing by PepA-P clearly implicates 
the role of aspartic proteinases in antigen processing which confirms the previous studies 
reporting the processing of TTC by cathepsin E and cathepsin D [15, 189], that are the major 
intracellular aspartic proteinases. 
Thus, in conclusion, pepstatin A- penetratin (PepA-P) conjugate can serve as an important new 
tool to investigate the role of aspartic proteinases in antigen processing and presentation in 
different antigen presenting cells. 
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4 
4 Recombinant cathepsin E has no proteolytic 
activity at neutral pH 
This chapter was published in:  
Biochem Biophys Res Commun. 2007 Aug 17;360(1):51-5.  
 
 
4.1 Abstract 
Cathepsin E (CatE) is a major intracellular aspartic protease, reported to be involved in cellular 
protein degradation and several pathological processes. Distinct cleavage specificities of CatE 
at neutral and acidic pH have been reported previously in studies using CatE purified from 
human gastric mucosa. Here, in contrast, we have analysed the proteolytic activity of 
recombinant CatE at acidic and neutral pH using two separate approaches, RP-HPLC and 
FRET-based proteinase assays. Our data clearly indicate that recombinant CatE does not 
possess any proteolytic activity at all at neutral pH and was unable to cleave the peptides 
glucagon, neurotensin and dynorphin A that were previously reported to be cleaved by CatE at 
neutral pH. Even in the presence of ATP, which is known to stabilize CatE, no proteolytic 
activity was observed. These discrepant results might be due to some contaminating factor 
present in the enzyme preparations used in previous studies or may reflect differences between 
recombinant CatE and the native enzyme 
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4.2 Introduction 
Cathepsin E (CatE, EC 3.4.23.34) is a non-lysosomal aspartic protease with a limited 
distribution in certain cell types, including gastric epithelial cells [33], macrophages [29], 
lymphocytes [29], microglia [34] and dendritic cells [12]. It is localized in different cellular 
compartments. In a number of cells it appears to be present in vesicular structures associated 
with the endoplasmic reticulum and Golgi apparatus [30, 34, 37]. It is also reported to be 
localized in endosomal structures [34] and the plasma membrane [36]. It is the active form of 
CatE that shows endosomal localization [190]. CatE plays an important role in MHC class II 
antigen processing pathway in B cells [13, 35], microglia [56] and dendritic cells [12]. CatE is 
also expressed in pancreatic ductal adenocarcinoma [77], and its presence in pancreatic juice is 
reported to be a diagnostic marker for this cancer [93]. Increased levels of CatE in neurons and 
glial cells of aged rats are suggested to be related to neuronal degeneration and reactivation of 
glial cells during the normal aging process of the brain [94]. CatE-deficient mice develop 
atopic dermatitis-like skin lesions [43] and are more susceptible to bacterial infection 
associated with decreased expression of multiple cell surface Toll-like receptors [44]. 
According to a most recent study [45], CatE deficiency induces a novel form of lysosomal 
storage disorder characterized by the accumulation of lysosomal membrane sialoglycoproteins 
and the elevation of lysosomal pH in macrophages. CatE is normally most active at acidic pH, 
which corresponds to active endosomal form, preferring substrates with bulky hydrophobic 
amino acids at P1 and P1′ positions [155]. However, according to some reports, CatE also 
retains activity at neutral pH [23, 24]. In reference [24], proteolytic activity and cleavage 
specificity towards the B chain of oxidized insulin was examined. It was reported that the 
cleavage specificity changed significantly with more specific cleavage at pH 7.4 and above, as 
compared to pH 5.5 and 3.0. At acidic pH, several peptide bonds, especially Phe-X, Tyr-X and 
Leu-X were cleaved, whereas at pH 7.4 the Glu13-Ala14 bond was selectively cleaved. In a 
more recent study [23], preferential cleavage of Arg-X and Glu-X bonds at pH 7.4 was 
reported, with the Arg-Arg bond the preferred cleavage site. 
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This reported unique specificity of CatE at pH 7.4, together with the fact that it is localized in 
different cellular compartments, suggested the possibility that it could be involved in 
processing or degradation of certain proteins and peptides at or near neutral pH in vivo. 
However, in all the studies reporting proteolytic activity of CatE at pH 7.4, the enzyme was 
isolated either from human gastric mucosa [22-24] or human red blood cells [22]. In the present 
study, we determined the proteolytic activity of recombinant CatE in order to avoid any 
possible contamination of the isolated enzyme with other factors. Peptide substrates such as 
glucagon, neurotensin and dynorphin A were used because these were previously reported to be 
hydrolysed by CatE at neutral pH [23]. The experiments were carried out with or without ATP, 
which is reported to stabilize CatE [22]. Our data clearly indicate that at neutral pH, 
recombinant human CatE shows no cleavage activity and is not stabilized by ATP. 
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4.3 Experimental procedures 
4.3.1  Materials 
Cathepsin E was purchased from R&D systems (Wiesbaden, Germany) and stored as 0.1 
mg/ml stock solution in 25 mM MES, 0.15 M NaCl, pH 6.5, and 50 % glycerol, at -20 °C. ATP 
was purchased from Sigma (Taufkirchen, Germany) prepared and used according to the 
instructions of the supplier. 
4.3.2 Solid-phase peptide synthesis 
The peptides HSQGTFTSDYSKYLDSRRAQDFVQWLMNT (Glucagon), ELYENKPRRP-
YIL (Neurotensin), and YGGFLRRIRPKLKWDNQ (Dynorphin A) were synthesized using 
standard Fmoc/tBu chemistry [191], performed on the multiple peptide synthesizer Syro II 
(MultiSynTech, Witten, Germany) on a 0.025-mmol scale using a 6-fold molar excess of Fmoc 
amino acids (MultiSynTech, Witten, Germany) on TCP-resin (PepChem, Reutlingen, 
Germany). All other reagents and solvents for peptide synthesis were purchased from Merck 
KGaA (Darmstadt, Germany). In situ activation was performed using TBTU (6 eq) 
and HOBt (1 eq), followed by the addition of N-methylmorpholine (12 eq) in N,N-
dimethylformamide. After completion of the automated synthesis, the resin-bound peptides 
were Fmoc-deprotected using 20% (v/v) piperidine in N,N-dimethylformamide twice for 15 
min and washed subsequently with N,N-dimethylformamide, isopropyl alcohol, and diethyl 
ether. To release the peptides from the resin and to remove the side chain protecting groups, the 
following solution was used: 92% (v/v) trifluoroacetic acid containing 3% (v/v) thioanisol, 3% 
(w/v) phenol, and 2% (v/v) ethanedithiol. The peptides were precipitated and washed twice in 
diethyl ether, dried, and dissolved in 80% (v/v) tert-butanol in water followed by lyophilization. 
Crude peptides were purified using preparative reversed-phase high performance liquid 
chromatography (RP-HPLC) and their identity was confirmed using MALDI-MS. Peptide 
purities were determined via analytical RP-HPLC and proved to be above 95%.  
A FRET-based peptide substrate derived from Glucagon sequence [Mca-KYLDSRRAQD-
FVQWL-K(Dnp)-NH2] was also synthesized. Peptide: KYLDSRRAQDFVQWL-K(Dnp)-NH2 
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was synthesized as described above. After Fmoc deprotection using piperidine, on-resin 
labelling of the peptides with Mca ((7-methoxycoumarin-4-yl)acetyl) was performed. The 
fluorophore Mca was coupled in a three-fold excess directly to the α-amino group of the side 
chain-protected resin-bound peptide in DMF using the TBTU/HOBt activation method for 3 h 
in the dark [192]. Subsequently the peptides were released from the resin and processed as 
described above. 
4.3.3 Digestion of peptides and analysis of digestion products using RP-HPLC  
Hydrolysis of each peptide substrate by cathepsin E and analysis of the resulting peptides were 
performed as follows. Neurotensin (5µg), glucagon (5µg) and dynorphin A (5µg) were digested 
in absence or presence of ATP (6.25mM) at 37°C for 18 hours with cathepsin E (10 or 50 ng) 
in 50 mM sodium phosphate buffer, pH 7.4, or 50 mM sodium acetate buffer, pH 4.0. The 
digestion experiments were performed simultaneously at pH 4.0 and pH 7.4, CatE was taken 
from the same stock aliquot and activated at pH 4.0 prior to digestion at different pH values as 
recommended by the suppliers (R&D systems). The reaction was terminated by addition of 25 
µl stop solution (95% (v/v) ACN, 1% (v/v) trifluoroacetic acid in water. 
Peptide fragments were separated via analytical RP-HPLC using a C18 column (150 × 2 mm, 
Reprosil 100, Dr. Maisch GmbH, Tuebingen, Germany) with the following solvent system: (A) 
0.055% (v/v) trifluoroacetic acid in H2O, and (B) 0.05% (v/v) trifluoroacetic acid in ACN/H2O 
(4:1, (v/v)). The column was eluted with a 20–80% gradient of solvent B for 40 min. UV 
detection was carried out at 214 nm (UV detector SPD-10AV, Shimadzu, Duisburg, Germany). 
Manually collected fractions were subsequently analyzed by MALDI-MS. 
4.3.4 MALDI-MS  
0.5 µl of each RP-HPLC fraction was mixed with 0.5 µl DHB-matrix (10 mg/ml (w/v) 2,5-
dihydroxybenzoic acid in 60 % (v/v) ethanol containing 0.1 % (v/v) TFA) and applied on a 
gold target for MALDI-MS using a MALDI time-of-flight system (Reflex IV, serial number: 
26159.00007, Bruker Daltonics, Bremen, Germany). Signals were generated by accumulating 
120 – 210 laser shots. Raw data were analyzed using the software Flex Analysis 2.4 (Bruker 
Daltonics). 
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4.3.5 FRET-based assay for the determination of cathepsin E cleavage activity 
Catalytic activity of CatE was determined fluorometrically by hydrolysis of the substrate Mca-
KYLDSRRAQDFVQWL-K(Dnp)-NH2. CatE (10 ng), was added to 80µl digestion buffer (50 
mM sodium acetate buffer, pH 4.0, or 50 mM sodium phosphate buffer, pH 7.4) and the 
reaction was started by addition of 1 nmol substrate (stock solution 1mM in DMSO, 1 µl of 
substrate solution was dissolved in 10µl of the buffer separately and then added to the reaction 
mixture). Progress of fluorescent product formation was recorded using a fluorescence reader 
(Tecan Spectra Fluor, Crailsheim, Germany) on kinetic mode at 37°C (λex =340, λem = 405). As 
a positive control for the Arg cleavage site, 0.1 µg trypsin was added to 80µl digestion buffer 
(50 mM NH4HCO3, pH 8.0) and the reaction was started by addition of 1µl substrate solution 
as describe above. 
 
4.4 Results and Discussion 
To investigate the proteolytic potential of recombinant CatE at neutral pH, the peptide 
substrates glucagon, neurotensin and dynorphin A, were tested. These peptides are previously 
reported to be cleaved at pH 7.4 [23]. Figure 1 shows the expected cleavage sites in these 
peptides at neutral pH.  
 
Figure 1.Sequence of different peptides used in the study and potential cathepsin E cleavage 
sites. All the potential CatE cleavage sites at pH 7.4 and the observed cleavage site at pH 4.0 
(glucagon) are printed in bold.  
Dynorphin A:
H-S-Q-G-T-F-T-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L-M-N-TGlucagon:
Y-G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q
Neurotensin: E-L-Y-E-N-K-P-R-R-P-Y-I-L 
pH 4.0 (observed)
pH 7.4(expected)
pH 7.4 (expected)
pH 7.4 (expected)
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Glucagon was digested in vitro with CatE and the peptide fragments thus generated were 
separated by RP-HPLC (Figure 2B-E) and identified by MALDI-MS (Table 1). Figure 2A 
shows the chromatogram of the undigested peptide substrate (glucagon) as a negative control. 
Figure 2B depicts the results of digestion of the glucagon with CatE at pH 4.0 in the presence 
of ATP at a concentration of 6.25mM, approximating that within the cells, and reported to 
stabilize CatE [22]. As expected, at acidic pH glucagon was cleaved between Phe-Val residues 
(Figure 2B, Table 1) as identified by MALDI-MS. Digestion of glucagon with CatE at pH 4.0 
without ATP (Figure 2C) yielded a similar RP-HPLC-profile as in the presence of ATP. In 
contrast, when digested at pH 7.4 no proteolytic activity was observed with or without ATP 
(Figure 2D-E, Table 1). 
 
Figure 2.  RP-HPLC profiles depicting digestion of synthetic glucagon peptide with CatE. 
(A) Undigested peptide. (B) Peptide digested with CatE (10ng) at pH 4 (0.05 M sodium acetate 
buffer) in  presence of ATP (6.25 mM). (C) Peptide digested with CatE (10ng) at pH 4.0 
without ATP. (D) Peptide digested with CatE (50ng) at pH 7.4 (0.05M sodium phosphate 
buffer) in the presence of ATP (6.25 mM). (E) Peptide digested with CatE (50ng) at pH 7.4 
without ATP.  Digestion of glucagon with CatE at pH 4.0 with or without ATP resulted in one 
cleavage reaction giving two peaks. Whereas, digestion at pH 7.4 with or without ATP showed 
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no cleavage activity even when 5 times larger amount of CatE was applied. Peaks were 
collected and peptides were analysed using MALDI-MS (see table 1). * corresponds to peptides 
with oxidized methionine.   
 
Neurotensin, previously reported to be cleaved at Arg-Arg, Lys-Pro, and Glu-Asn (Figure 1)  
[23] by human CatE at pH 7.4 was also examined (Figure 3). Again no cleavage activity was 
observed at pH 7.4 with or without ATP (Figure 3 B-C, Table 1). Finally, digestion of 
dynorphin A with CatE at pH 7.4 also showed no proteolytic activity with or without ATP 
(Table 1). 
Figure 3. RP-HPLC profiles depicting digestion of synthetic neurotensin peptide with CatE. 
(A) Undigested peptide (B) Peptide digested with CatE (50ng) at pH 7.4 (0.05M sodium 
phosphate buffer) in the presence of ATP (6.25 mM). (C) Peptide digested with CatE (50ng) at 
pH 7.4 without ATP.   
 
In order to confirm the above mentioned results another approach, i.e FRET-based proteinase 
assay, was used for determining proteolytic activity at neutral pH. According to the sequence of 
glucagon, a FRET-based peptide substrate for CatE i.e. Mca-KYLDSRRAQDFVQWL-
K(Dnp)-NH2 [where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is dinitrophenyl] was 
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synthesized. It is an intramolecularly-quenched fluorogenic peptide derivative in which the 
fluorescent signal of the fluorophore Mca is quenched by the chromophoric residue Dnp. After 
cleavage of the peptide, the quenching efficiency is decreased, resulting in an increase in 
fluorescence. Using this substrate, cleavage activity of CatE at pH 7.4 and 4.0 was determined. 
As shown in Figure 4, no increase in fluorescence was observed at pH 7.4 whereas at pH 4.0 
there was a rapid increase. To have a positive control for the Arg cleavage site trypsin was 
included in the experiment as it cleaves C-terminal to Arg residues. As also shown in Figure 4, 
trypsin cleaved the substrate efficiently at pH 8.0. 
 
Figure 4. FRET-based assay for the determination of CatE cleavage activity at pH 4.0 and 
7.4. Hydrolysis of the fluorogenic peptide substrate based on glucagon sequence (Mca-
KYLDSRRAQDFVQWL-K(Dnp)-NH2)(1µM) by 10 ng of CatE in 50mM sodium acetate buffer 
(pH 4) at 37°C. or 0.05M sodium phosphate buffer (pH 7.4) at 37°C or 0.1 µg of trypsin in 
50mM NH4HCO3 (pH 8.0). Control is the sample containing only the substrate and no enzyme.  
 
Our results fail to reveal any proteolytic activity of recombinant CatE at neutral pH even in the 
presence of ATP. Thus, the purified enzyme used in previous studies [18, 19] might have been 
contaminated with some other factor. Alternatively, these discrepant results may reflect 
conformational differences between recombinant CatE and the native enzyme. These 
differences may also arise from posttranslational modification of the native enzyme in vivo.  
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Table 1.  Identified peptides after digestion of neurotensin, glucagon, and dynorphin A by 
CatE, as determined by MALDI-MS (digestion experiments performed in the presence of 6.25 
mM ATP). 
[M+H]+ Substrate pH Peptides  identified by MALDI-MS Theoretical Observed 
Retention 
time 
4 
 
HSQGTFTSDYSKYLDSRRAQ-
DF 
VQWLMNT 
Glucagon (uncleaved) 
 
2609.77 
891.06 
3482.82 
 
2609.39 
891.06 
3481.95 
 
15.8 
17.67 
22.38 
Glucagon 
HSQGTFTSDYSKYL-
DSRRAQDFVQWLMNT 
 
7.4 
 
No cleavage activity was observed. 
Only undigested glucagon 
recovered. 
 
3482.82 
 
3481.86 
 
22.49 
Neurotensin   
ELYENKPRRPYIL 
7.4 
 
No cleavage activity was observed. 
Only undigested neurotensin 
recovered. 
1690.98 1690.88 15.55 
Dynorphin A 
YGGFLRRIRPKLKWD-
NQ 
7.4 
 
No cleavage activity was observed. 
Only undigested dynorphin A 
recovered. 
2147.53 2147.53 
 
17.60 
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5 
5 . Substrate profiling of Cathepsin E and D 
 
 
5.1 Abstract 
The substrate specificities of cathepsin E and D were studied in detail. Previously described 
peptide substrate for CatE and CatD i.e. G-K-P-IP3-LP2-FP1-FP1´-RP1´-LP1´ (digested at Phe-Phe 
bond, by both CatE and CatD) was modified systematically.  Positions P1, P2, P3, P1´, P2´ and 
P3´ of this substrate were each substituted with 20 different naturally occurring amino acid 
residues and norleucine. Screening of several peptides provided distinct amino acid preferences 
by cathepsin E and D. It was identified that within a limited range of enzyme concentration (0-
5nM) and time (0-120 min) provided for hydrolysis, peptides with basic residues at position P3 
were only cleaved by cathepsin E. But these peptides were also cleaved by CatD at higher 
concentration and after longer incubation time. Thus, we were unable to identify exclusively 
specific substrates for either CatE or CatD but, the detailed screening provides better 
understanding of the substrate specificity profiles of the two cathepsins. This study provides 
useful information for developing specific substrates and selective inhibitors for these two 
otherwise very similar proteases. 
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5.2 Introduction 
Proteases, also referred as proteolytic enzymes or proteinases, constitute one of the largest and 
most important protein families. They are of great relevance to biology, medicine and 
biotechnology. The catalytic function of proteases is to hydrolyze amide bonds in proteins and 
peptides. They differ in their ability to hydrolyze various peptide bonds.  The biological 
significance of proteases is illustrated by the fact that they comprise over 2% of the human 
genome [193]. An important feature of any protease is its substrate specificity that results in 
preferential cleavage of its specific substrate in presence of several other proteins and peptides. 
Therefore, specificity information gives a better understating of the physiological role of any 
protease and also helps in designing the specific substrates and selective inhibitors. 
Cathepsins E and D are the major aspartic proteinases in the endolysosomal pathway. These 
enzymes have been implicated in in several physiological processes and as well as in 
pathalogical conditions [194, 195]. They have similar enzymatic properties, e.g. susceptibility 
to various proteinase inhibitors, similar substrate preferences [155] and similar pH optimum. 
Previous reports have described highly selective substrates for aspartic proteinases, but none of 
the described substrates is exclusively specific for CatE or CatD [19, 20, 156]. It is known that 
cathepsin E and cathepsin D both prefers hydrophobic amino acids at P1 and P1` positions. For 
cathepsin E, β-branched residues, e.g. V and I are not allowed at P1 [28]  while position P2´ 
accepts a broad range of amino acids, including charged and polar ones [28]. For CatE, a basic 
residue e.g. K is acceptable at position P2, which is not the case for CatD [64]. The presence of 
proline at P4 seems to be important for CatE  [17]. For CatD, leucine is strongly favoured at 
P1, at P2 and P1´ the hydrophobic requirements are less strict [27]. A charged preferably basic 
residue is found mostly at ´positions P2´and P5; at least 1 basic residue appears to be required 
by CatD at either position [27].  
On the basis of available information about substrate specificity, several synthetic chromogenic 
or fluorogenic substrates have been developed to measure CatE or CatD activity [19, 68-70]. 
These methods are simple and fast, but the described substrates are restricted in their 
selectivity. Recently, a new selective substrate for cathepsin E, based on the cleavage site 
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sequence of α2-macroglobulin, has been described [87]. However, this substrate was also not 
exclusive for CatE because it had low level of activity for CatD and pepsin as well. In order to 
understand the physiological role and enzymatic properties of cathepsin E and D in detail, there 
is an urgent need of a specific and sensitive substrate for each of these enzymes. 
In this study, substrate specificity of cathepsin E and D was examined in detail. To achieve this 
the most commonly used  substrate for CatE and CatD, G-K-P-IP3-LP2-FP1-FP1´-RP1´-LP1´[19] 
(digested at Phe-Phe bond, by both CatE and CatD) was modified systematically.  Positions P1, 
P2, P3, P1´, P2´ and P3´ of this substrate were each substituted with 20 different naturally 
occurring amino acid residues and norleucine. Although, no exclusively specific substrates for 
either CatE or CatD were identified but, the detailed screening offers a better understanding of 
the substrate specificity profiles for the two enzymes. The presented data will facilitate in 
designing  specific substrates or selective inhibitors of cathepsin E and D.  
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5.3 Experimental procedures 
5.3.1 Enzymes and chemicals 
Cathepsin E was purchased from R&D systems (Wiesbaden, Germany) and stored as 0.1 
mg/ml stock solution in 25 mM MES, 0.15 M NaCl, pH 6.5, and 50 % glycerol, at -20 °C. 
CatD (bovine kidney) was purchased from Calbiochem (Darmstadt, Germany) and stored as a 
0.4 mg/ml stock solution in 0.1 M citrate buffer, pH 4.5, at -20 °C. 
5.3.2 Solid-phase peptide synthesis  
The peptides GKPILFFRX, GKPILFFXL, GKPILFXRL, GKPILXFRL, GKPIXFFRL and 
GKPXLFFRL (were X represents any of the 20 naturally occurring amino acids or norleucine) 
were synthesized using standard Fmoc/tBu chemistry [191], performed on the multiple peptide 
synthesizer Syro II (MultiSynTech, Witten, Germany) on a 0.025-mmol scale using a 6-fold 
molar excess of Fmoc amino acids (MultiSynTech, Witten, Germany) on TCP-resin (PepChem, 
Reutlingen, Germany). For the position X, a mixture of five different amino acids was loaded. 
Thus, a total of 23 peptide series each containing 5 different peptides were synthesized. All 
reagents and solvents for peptide synthesis were purchased from Merck KGaA (Darmstadt, 
Germany). In situ activation was performed using TBTU (6 eq) and HOBt (1 eq) followed by 
the addition of N-methylmorpholine (12 eq) in N,N-dimethylformamide. After completion of 
the automated synthesis, the resin-bound peptides were Fmoc-deprotected using 20% (v/v) 
piperidine in N,N-dimethylformamide twice for 15 min and washed subsequently with N,N-
dimethylformamide, isopropyl alcohol, and diethyl ether. To release the peptides from the resin 
and to remove the side chain protecting groups, the following solution was used: 92% (v/v) 
trifluoroacetic acid containing 3% (v/v) thioanisol, 3% (w/v) phenol, and 2% (v/v) 
ethanedithiol. The peptides were precipitated and washed twice in diethyl ether, dried, and 
dissolved in 80% (v/v) tert-butanol in water followed by lyophilization. Peptides were 
seperated using preparative reversed-phase high performance liquid chromatography (RP-
HPLC) and their identity was confirmed using MALDI-MS. Peptide purities were determined 
via analytical RP-HPLC and proved to be above 95%. 
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FRET-based peptide substrates Mca-Gly-Lys-Pro-His-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-
NH2, Mca-Gly-Lys-Pro-Lys-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 and Mca-Gly-Lys-
Pro-Arg-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 were synthesized. The peptides without 
Mca were synthesized as described above. After Fmoc-deprotection using piperidine, on-resin 
labeling of the peptides with Mca ((7-methoxycoumarin-4-yl)acetyl) was performed. The 
fluorophor Mca was coupled at a three-fold excess directly to the α-amino group of the side 
chain-protected resin-bound peptide in DMF using the TBTU/HOBt activation method for 3 h in 
the dark [192]. Subsequently, the peptides were released from the resin and processed as 
described above. 
5.3.3 Digestion of peptides and analysis of digestion products 
 Hydrolysis of each peptide substrate by cathepsin E or D and analysis of the resulting peptides 
were performed as follows. All the peptides were digested at 37°C for30 min with CatE (1.19 
nM) or with CatD (4 nM) in 50 mM sodium acetate buffer, pH 4.0. The concentration of CatE 
(1.19 nM) and CatD (4 nM) for each reaction were chosen, as these amounts of enzymes were 
able to digest 50% of the control peptide (GKPILFFRL) in 30 min. The reactions were 
terminated by boiling the samples for 5 min at 98°C. 
Peptide fragments were separated via analytical RP-HPLC using a C18 column (150 × 2 mm, 
Reprosil 100, Dr. Maisch GmbH, Tuebingen, Germany) with the following solvent system: (A) 
0.055% (v/v) trifluoroacetic acid in H2O, and (B) 0.05% (v/v) trifluoroacetic acid in ACN/H2O 
(4:1, (v/v)). The column was eluted with a 20–80% gradient of solvent B for 40 min. UV 
detection was carried out at 214 nm (UV detector SPD-10AV, Shimadzu, Duisburg, Germany). 
5.3.4 MALDI-MS 
0.5 µl of each RP-HPLC fraction was mixed with 0.5 µl DHB-matrix (10 mg/ml (w/v) 2,5-
dihydroxybenzoic acid in 60 % (v/v) ethanol containing 0.1 % (v/v) TFA) and applied on a 
gold target for MALDI-MS using a MALDI time-of-flight system (Reflex IV, serial number: 
26159.00007, Bruker Daltonics, Bremen, Germany). Signals were generated by accumulating 
120 – 210 laser shots. Raw data were analyzed using the software Flex Analysis 2.4 (Bruker 
Daltonics).
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5.4 Results and Discussion 
5.4.1 Synthesis of peptide libraries 
Different peptide series were synthesized for substrate profiling of CatE and CatD. To achieve 
this, the previously described peptide substrate Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu [19] 
which is digested at Phe-Phe bond, by both CatE and CatD was manipulated. The positions P1, 
P2, P3, P1´ P2´ and P3´ of this peptide were each substituted with 20 different naturally 
occurring amino acids and norleucine. Five peptides were synthesized together in one series as 
described in experimental procedures. The peptides were separated by means of preparative 
RP-HPLC; five fractions were separately collected, lyophilized and identified by MALDI-MS 
(Figure 1). Some of the synthesized peptides were lost during the processes of synthesis, 
separation or purification. Table 1 shows the sequence and characteristics of all the synthesized 
peptides that were recovered from different peptide series and analysed by digestion 
experiments. The coding system of peptides is also explained in Figure 1. 
 
 
Figure 1. Schematic representation of synthesis, purification and coding of the peptides. Five 
peptides were synthesized simultaneously  in one series. For the altering amino acid a mixture 
of five amino acids was loaded on the peptide resin (the representative scheme shows altering 
P2 position). Peptides were separated and purified via preparative RP-HPLC and identified by 
MALDI-MS and named according to the variation related to the control peptide 
(GKPILFFRL), e.g., when position P2 was substituted with K, the peptide is named P2K. 
 
 
 
Results and Discussion 
87  
 
 
 
Table 1. Peptides analyzed in the present study.   
Peptide 
I.D 
Peptides Expected 
Weight 
Observed 
Weight 
∆Da Retention Time 
(min) 
P3´ 
P3´H GKPILFFRH 1114.37 1114.71 0.34 28.24 
P3´S GKPILFFRS 1064.31 1064.69 0.38 29.47 
P3´V GKPILFFRV 1076.36 1076.79 0.43 32.92 
P3´F GKPILFFRF 1124.41 1124.81 0.40 36.83 
P3´K GKPILFFRK 1105.40 1105.50 0.10 16.30 
P3´Q GKPILFFRQ 1105.36 1150.53 0.17 18.14 
P3´D GKPILFFRD 1092.32 1092.50 0.18 19.29 
P3´W GKPILFFRW 1163.44 1163.59 0.15 32.86 
P3´R GKPILFFRR 1133.42 1133.95 0.53 10.90 
P3´A GKPILFFRA 1048.31 1048.87 0.56 15.59 
P3´M GKPILFFRM 1108.42 1108.89 0.47 17.03 
P3´I GKPILFFRI 1090.39 1090.88 0.49 17.63 
P3´N GKPILFFRN 1091.33 1091.43 0.10 17.14 
P3´E GKPILFFRE 1106.34 1106.60 0.26 18.06 
P3´T GKPILFFRT 1078.33 1078.53 0.20 18.54 
P3´Y GKPILFFRY 1140.40 1140.48 0.08 21.23 
P3´L GKPILFFRL 1090.39 1090.54 0.15 27.82 
P2´ 
P2´H GKPILFFHL 1071.34 1071.42 0.08 24.14 
P2´S GKPILFFSL 1021.28 1021.38 0.10 28.12 
P2´G GKPILFFGL 991.25 991.37 0.12 29.08 
P2´V GKPILFFVL 1033.33 1033.59 0.26 36.30 
P2´F GKPILFFFL 1081.38 1081.51 0.13 44.08 
P2´K GKPILFFKL 1062.37 1062.34 0.01 14.52 
P2´Q GKPILFFQL 1062.33 1062.41 0.08 20.35 
P2´D GKPILFFDL 1049.29 1049.37 0.08 21.92 
P2´Nle GKPILFFnL 1047.36 1047.44 0.08 30.78 
P2´W GKPILFFWL 1120.41 1120.67 0.26 32.61 
P2´R GKPILFFRL 1090.39 1090.56 0.17 30.60 
P2´P GKPILFFPL 1031.32 1031.54 0.22 35.70 
P2´I GKPILFFIL 1047.36 1047.75 0.39 42.17 
P2´N GKPILFFNL 1048.30 1048.72 0.42 24.80 
P2´Y GKPILFFYL 1097.38 1097.57 0.19 30.57 
P2´L GKPILFFLL 1047.36 1047.57 0.21 35.58 
P1´ 
P1´H GKPILFHRL 1080.35 1080.60 0.25 16.90 
P1´G GKPILFGRL 1000.26 1000.59 0.33 22.11 
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P1´V GKPILFVRL 1042.34 1042.59 0.25 26.92 
P1´F GKPILFFRL 1090.39 1090.61 0.22 31.98 
P1´K GKPILFKRL 1071.38 1071.36 0.02 17.96 
P1´Q GKPILFQRL 1071.34 1071.85 0.51 23.08 
P1´D GKPILFDRL 1058.30 1058.39 0.09 24.15 
P1´W GKPILFWRL 1129.42 1129.60 0.18 33.31 
P1´R GKPILFRRL 1099.40 1099.40 0.00 18.85 
P1´A GKPILFARL 1014.29 1015.01 0.72 24.00 
P1´P GKPILFPRL 1040.33 1040.87 0.54 24.74 
P1´M GKPILFMRL 1074.41 1074.99 0.58 28.90 
P1´I GKPILFIRL 1056.37 1056.88 0.51 30.24 
P1´N GKPILFNRL 1057.31 1057.48 0.17 7.92 
P1´F GKPILFERL 1072.33 1072.66 0.33 9.14 
P1´Y GKPILFYRL 1106.39 1106.65 0.26 11.74 
P1´L GKPILFLRL 1056.37 1056.65 0.28 15.98 
P1 
P1H GKPILHFRL 1080.35 1080.76 0.41 8.27 
P1G GKPILGFRL 1000.26 1000.72 0.46 10.92 
P1S GKPILSFRL 1030.29 1030.64 0.35 10.99 
P1V GKPILVFRL 1042.34 1042.77 0.43 16.03 
P1F GKPILFFRL 1090.39 1090.83 0.44 19.88 
P1K GKPILKFRL 1071.38 1071.79 0.41 7.66 
P1Q GKPILQFRL 1071.34 1071.93 0.59 10.97 
P1D GKPILDFRL 1058.30 1058.76 0.46 12.26 
P1X GKPILXFRL 1056.37 1056.88 0.51 18.26 
P1W GKPILWFRL 1129.42 1129.72 0.30 20.72 
P1R GKPILRFRL 1099.40 1099.84 0.44 8.44 
P1A GKPILAFRL 1014.29 1014.76 0.47 11.72 
P1P GKPILPFRL 1040.33 1040.80 0.47 13.44 
P1M GKPILMFRL 1074.41 1074.81 0.40 16.18 
P1I GKPILIFRL 1056.37 1056.82 0.45 17.90 
P1N GKPILNFRL 1057.31 1058.03 0.28 10.71 
P1E GKPILEFRL 1072.33 1072.77 0.44 12.43 
P1Y GKPILYFRL 1106.39 1106.92 0.53 14.51 
P1L GKPILLFRL 1056.37 1056.89 0.52 18.72 
P2 
P2H GKPIHFFRL 1114.37 1114.70 0.33 10.67 
P2G GKPIGFFRL 1034.28 1034.65 0.37 14.40 
P2S GKPISFFRL 1064.31 1064.69 0.38 14.49 
P2V GKPIVFFRL 1076.36 1076.81 0.45 18.37 
P2F GKPIFFFRL 1124.41 1124.84 0.43 23.09 
P2K GKPIKFFRL 1105.40 1105.87 0.47 11.91 
Results and Discussion 
89  
 
 
P2Q GKPIQFFRL 1105.36 1105.86 0.50 16.90 
P2D GKPIDFFRL 1092.32 1092.84 0.52 19.00 
P2Nle GKPInFFRL 1090.39 1090.91 0.52 24.41 
P2W GKPIWFFRL 1163.44 1163.93 0.49 27.22 
P2R GKPIRFFRL 1133.42 1133.51 0.09 9.97 
P2A GKPIAFFRL 1048.31 1048.46 0.15 13.79 
P2P GKPIPFFRL 1074.34 1074.48 0.14 15.03 
P2M GKPIMFFRL 1108.42 1108.51 0.09 18.40 
P2I GKPIIFFRL 1090.39 1090.45 0.06 19.99 
P2N GKPINFFRL 1091.33 1091.44 0.11 11.80 
P2E GKPIEFFRL 1106.34 1106.54 0.20 11.89 
P2Y GKPIYFFRL 1140.40 1140.62 0.22 15.28 
P2L GKPILFFRL 1090.39 1090.63 0.24 18.56 
P3 
P3H GKPHLFFRL 1114.37 1114.48 0.11 8.83 
P3G GKPGLFFRL 1034.28 1034.53 0.25 11.34 
P3V GKPVLFFRL 1076.36 1076.31 0.05 15.53 
P3F GKPFLFFRL 1124.41 1124.62 0.21 19.83 
P3K GKPKLFFRL 1105.40 1105.56 0.16 12.78 
P3Q GKPQLFFRL 1105.36 1105.74 0.38 16.51 
P3D GKPDLFFRL 1092.32 1092.66 0.34 17.26 
P3Nle GKPnLFFRL 1090.39 1090.72 0.33 23.63 
P3W GKPWLFFRL 1163.44 1163.69 0.25 26.36 
P3R GKPRLFFRL 1133.42 1133.73 0.31 5.41 
P3A GKPALFFRL 1048.31 1048.57 0.26 7.14 
P3P GKPPLFFRL 1074.34 1074.66 0.32 7.19 
P3M GKPMLFFRL 1108.42 1108.51 0.09 11.62 
P3I GKPILFFRL 1090.39 1090.24 0.15 13.34 
P3N GKPNLFFRL 1091.33 1091.28 0.05 4.56 
P3E GKPELFFRL 1106.34 1106.32 0.02 5.48 
P3H GKPYLFFRL 1140.40 1140.40 0.00 8.23 
P3L GKPLLFFRL 1090.39 1090.41 0.02 10.72 
5.4.2 Screening of the peptide libraries for the selection of preferable substrates 
for cathepsin E or D 
In the first step of screening all peptides were digested with cathepsin E (1.19 nM) and D (4 
nM) for 30min as described in materials and methods. The digestion products were separated 
by analytical RP-HPLC and the digestion percentage was calculated by area of digestion peaks 
and starting material (uncleaved substrate) (Figure 2).  
Chapter 5. Substrate profiling of cathepsin E and D 
 
 
90 
 
Figure 2. Calculation of digestion percentage for a peptide substrate using area of digestion 
peaks and uncleaved residual substrate peak on RP-HPLC chromatograms. Chromatograms 
represent peptide P3H, (A) Undigested, (B) Digested with cathepsin E (1.19 nM) for 60 min. 
Total area for both the chromatograms is similar. Therefore, it can be used to calculate the 
digestion percentage. Digestion % was calculated using the following formula: 
Digestion % =      Area of digestion peak 1 + Area of digestion peak 2    x 100 
                                                            Total area 
For the represented case: 
Digestion percentage = 82152 + 228248    x 100   = 91.09% 
                                           340733 
 
As shown in Figures 3A and B, both enzymes showed similar preferences for P1 positions. F, 
n (norleucine), M and L were the most preferable amino acids at this position. Whereas, I and 
V were not allowed at this position which is consistent with previously published studies [28]. 
For P1´, CatE accommodated a relatively broader range of residues, but like CatD, a higher 
preference was observed for F, M and I (Figures 3C and D). Thus, no significant difference 
was observed for these positions with the exception of the peptide P1´P: P at P1´ was not 
allowed for cleavage by CatD, but CatE allowed this residue. The digestion was comparatively 
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low (<10%), but specific for CatE. Therefore this peptide was selected for second stage of 
screening. 
The digestion profile for the peptides varying at P2 position was slightly different for CatE and 
CatD. The amino acid G and the basic residues H, K and R were not allowed for cleavage by 
CatD at this position, but CatE accepted these residues, though the degree of digestion was 
lower in comparison to the control peptide (Figures 3E and F). Thus, peptides P2G, P2H, P2K 
and P2R were selected for second stage of screening. Moreover, preference for the resides, S, 
V, Q, D, and W was also different between CatE and D. For these residues, CatE showed a 
higher degree of digestion compared to CatD that was minimal in comparison to the control 
peptide. 
The digestion pattern for the peptides varying at P2´position was similar for both, CatE and 
CatD, therefore, from this series none of the peptides were further pursued (Figures 2G and 
H).  
The peptides with basic residues at position P3 also showed differences in digestion pattern 
between CatE and CatD. The basic residues H, K, and R at this position were not allowed for 
cleavage by CatD, but were accommodated by CatE. Thus, the peptides P3K, P3R and P3H 
were selected for second stage of screening (Figures 3I and J). 
For the position P3´, the only differences between CatE and D were for the residue R. Again, 
this residue was allowed for cleavage by CatE, but not CatD. The corresponding peptide P3´R 
was selected for second stage of screening (Figures 3K and L). 
The peptides selected after first stage of screening, i.e. P2H, P2G, P2K, P2R, P3H, P3K, P3R, 
P1´P and P3´R were all more or less specific for CatE. Unfortunately, we were unable to find 
any specific substrate for CatD among the peptides analysed in the present study.   
In the second stage of screening, all the selected peptides were digested by CatE under similar 
conditions as described above for preliminary screening. On the other hand, the digestion time 
for CatD was increased to 120 min in order to confirm the specificity of the selected peptide for 
CatE. 
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Figures 4A and B show the digestion profiles for the selected peptides by CatD and CatE, 
respectively. It was observed that even after 120 min of incubation with cathepsin D (4 nM), 
the peptides with basic residues at P3 position i.e. P3H, P3K and P3R were not cleaved. 
Moreover, the only cleavage site for CatE in these peptides was between two phenylalanine 
residues as determined by RP-HPLC and MALDI.MS. These substrates were further 
investigated as potential specific substrate for CatE. 
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Figure 3. Preliminary screening of peptide series for determination of substrate specificity of 
cathepsin E and D.  All the peptides were digested with CatE (1.19 nM) or CatD (5 nM) for 30 
min at 37°C in digestion buffer (50 mM sodium acetate buffer, pH 4.0). The digestion products 
were separated by RP-HPLC and the digestion percentage was calculated as described in 
Figure 2. The digestion percentage (vertical axis) is plotted for different peptides as indicated on 
the horizontal axis. White bars indicate the peptides which were specifically cleaved by CatE 
and selected for second stage of screening, whereas the grey bar in each panel indicates the 
control peptide. Values depicted are means ± SD (n = 2) where n is the number of individual 
experiments. 
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Figure 4. Digestion of the peptides selected after preliminary screening with cathepsin E and 
D. The peptides that were specifically cleaved by CatE in preliminary screening were subjected 
to second stage of screening. All the peptides were digested with CatE (30min) or CatD (120 
min) (for experimental details see legend to figure 1). Values depicted are means ± SD (n = 3). 
It was observed that peptides with basic amino acid residues at P3 position i.e. P3H, P3R and 
P3K were not cleaved by CatD even after 2 hours of incubation. These peptides were further 
pursued for their potential as specific CatE substrates. 
 
5.4.3 Effect of incubation time, enzyme concentration and pH and on hydrolysis 
of selected substrates by cathepsin E and D 
The substrates selected to be specific for cathepsin E after screening i.e. P3H, P3K and P3R 
were subjected to further investigation. The effects of incubation time, enzyme concentration 
and pH on hydrolysis of selected substrate by cathepsin E and D were studied. As mentioned 
above, after 120 min of incubation with cathepsin D in second stage of screening, these 
substrates were not cleaved, whereas CatE hydrolyzed approximately 30-50% of these peptide 
substrates within 30 minutes.  
The selected substrates were incubated with cathepsin E and D for different time points (60-300 
min). It was observed that after 180 min of incubation with cathepsin D all the substrates were 
digested (Figure 5 A).  
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Figure 5. Digestion of the selected peptides (i.e. GKPHLFFRL, GKPKLFFRL and 
GKPRLFFRL) with (A) CatD (B) CatE at different time points. Substrates P3H, P3K, P3R, 
and the control peptide were each incubated with CatE (1.19 nm) or CatD (4nm) at 37°C in 
digestion buffer (50 mM sodium acetate buffer, pH 4.0) for different time points (0-300 min). 
The substrates that were previously observed to be specific towards CatE (i.e. P3H, P3K and 
P3R) after 120 min of incubation were found to be digested even with CatD when incubation 
time was increased to 180 min. 
 
Moreover, the selected substrates were also incubated with increasing concentrations of CatE 
and CatD. It was observed that the selected substrates were cleaved also by cathepsin D above 
the concentration of 6nM after 30 min of incubation (Figure 6 A). Thus, the above described 
specificity of the selected substrates for CatE was limited to the lower concentration of 
enzymes and shorter incubation time provided for hydrolysis. This is the major drawback as in 
physiological conditions the concentration of cathepsin D is higher than cathepsin E. Therefore, 
the selected substrates might show selectivity towards cathepsin E, but are not exclusively 
specific for cathepsin E.  
The pH dependence of the hydrolysis of the selected substrates by CatE and CatD was also 
examined. In concordance with previous reports [20, 196] both, CatE and CatD gave their 
maximal activity at pH 4. At pH 2.0, CatE showed less than 15% of its maximum activity 
whereas CatD was completely inactive (Figures 7 A-B) (the point of maximum activity was 
taken 100%. In each case, reaction was much slower for of CatD). 
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Figure 6. Digestion of selected peptides with different concentration of (A) CatD and (B) 
CatE. Substrates, selected to be specific for CatE  after preliminary screening  (i.e. P3H, P3K 
andP3R), and the control peptide were each incubated at 37°C in digestion buffer (50 mM 
sodium acetate buffer, pH 4.0) for 30 min with increasing concentrations of CatE or CatD (2-10 
nm).Each substrate was cleaved by CatD above 6 nm concentration.  
Figure 7. Digestion of the selected peptides with of (A) CatD and (B) CatE at different pH values. . 
Substrates P3H, P3K, P3R, and the control peptide were each incubated with CatE (1.19 nm) 
or CatD (4nm) at 37°C for 30 min at different pH values. (the point of maximum activity was 
taken 100%. Iin each case reaction was much slower for CatD). 
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5.4.4 FRET labeling of the selected substrates 
The selected substrates (i.e. P3H, P3K and P3R) were also synthesized as FRET-based peptides 
[Mca-GKPHLFFRL-Lys(Dnp)-DArg-NH2, Mca-GKPKLFFRL-Lys(Dnp)-DArg-NH2 and Mca-
GKPRLFFRL-Lys(Dnp)-DArg-NH2 where Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is 
dinitrophenyl] to study the kinetic parameters.  
 
Figure 7. Digestion of the FRET-based peptides by (A) CatD and (B) CatE at different time points. 
Substrates P3H, P3K, P3R, and the control peptide were each synthesized as FRET-based peptide 
(Mca/Dnp type). These substrates were each incubated with CatE (1 nm) or CatD (1 nm) at 
37°C for different time points. All of these substrates were cleaved by both, cathepsin E and D 
equally.  
It was observed that the unlabelled peptides with the similar sequence that were found to be 
selective for CatE (i.e. GKPHLFFRL, GKPKLFFRL and GKPRLFFRL) when synthesized as 
FRET-based substrates (Mca/Dnp type) lost their specificity and were cleaved by both, cathepsin 
E and D equally (Figures 7A and B). The reaction was completed in 2 hours with both, CatE 
and CatD, as observed by fluorescence (no increase in fluorescence was detected after 2 hours). 
The loss of specificity of these substrates for CatE can not be explained with our data, but we 
speculate that it is due to change of conformation of the lengthed peptides. 
 
The investigations, presented in this chapter, on the substrate G-K-P-IP3-LP2-FP1-FP1´-RP1´-LP1, 
modified systematically at positions P1, P2, P3, P1´ P2´, and P3, allows detailed and accurate 
mapping of the substrate specificity profiles of cathepsin E and D. It was observed that cathepsin 
E prefers basic residues especially at position P3. We were unable to identify exclusively 
specific substrates for either CatE or CatD, but the presented data provide a better understanding 
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of their substrate specificity profile. These results can be used for designing of specific substrates 
and selective inhibitors for cathepsin E and D. 
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6.1 Key findings and conclusions: 
The studies based at understanding the role of cathepsin E and D are limited by two major 
obstacles; one is the absence of an assay or substrate that distinguishes between the two enzymes 
in crude biological samples. Second is the absence of a specific inhibitor. In the present thesis 
both of these problems have been addressed. . 
Following are the major goals accomplished during the course of this PhD project. 
• This thesis presents an assay combining a new monospecific CatE antibody and 
substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 [where 
Mca is (7-methoxycoumarin-4-yl)acetyl and Dnp is dinitrophenyl]. This substrate is 
digested by both proteinases and therefore can be used to detect the total aspartic 
proteinase activity (TAPA) in biological samples. After depletion of CatE by 
immunoprecipitation, the remaining activity is due to CatD, and the decrease of activity 
can be assigned to CatE. This assay distinguishes between the activities of 
enzymatically similar proteinases CatE and CatD and therefore can be used in studies 
aimed at understanding the involvement of these enzymes in antigen processing and 
presentation. 
• Using the above described assay, the activity of CatE and CatD in cytosolic, endosomal 
and lysosomal fractions of B cells, dendritic cells and human keratinocytes was 
determined. The data clearly indicates that CatE activity is mainly located in endosomal 
and that of CatD in lysosomal compartments. Hence, this assay can also be used for 
characterization of subcellular fractions using CatE as an endosomal marker, whereas 
CatD is a well-known lysosomal marker. 
• New cell permeable aspartic protease inhibitors were synthesized by conjugating 
pepstatin A with well-known cell-penetrating peptides (CPPs). To achieve this, the most 
frequently used CPPs, namely pAntp(43-58) (penetratin),  Tat(49-60), and 9-mer of L-
arginine (R9) were synthesized followed by coupling pepstatin A to the peptides. The 
enzyme inhibition properties of these bioconjugates and their cellular uptake into MCF7 
(human breast cancer cell line), Boleths (EBV-transformed B cell line) and dendritic 
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cells (DC) was studied. It was found that the bioconjugate PepA-penetratin (PepA-P) 
was the most efficient cell-permeable aspartic protease inhibitor in comparison to PepA. 
Additionally, we found that PepA-P efficiently inhibited the tetanus toxoid C-fragment 
processing in peripheral blood mononuclear cells (PBMC), primary DC and in primary 
B cells. This inhibition of tetanus toxoid C-fragment processing by PepA-P clearly 
implicates the role of aspartic proteinases in antigen processing. 
• In some of the previous studies, distinct cleavage specificities of CatE at neutral and 
acidic pH have been reported. Here, the proteolytic activity of recombinant CatE at 
acidic and neutral pH using two separate approaches, RP-HPLC and FRET-based 
proteinase assays, was determined. The data clearly indicated that recombinant CatE 
does not possess any proteolytic activity at neutral pH and was unable to cleave the 
peptides glucagon, neurotensin and dynorphin A that were previously reported to be 
cleaved by CatE at neutral pH. These discrepant results might be due to some 
contaminating factor present in the enzyme preparations used in previous studies or may 
reflect differences between recombinant CatE and the native enzyme. 
• The substrate profiling of cathepsin E and D was performed in detail. It was found that 
presence of basic residues i.e. R, K and H especially at position P3 is preferred by 
cathepsin E. Unfortunately we were unable to identify exclusive substrate for CatE or 
D. However, the detailed specificity profiling of cathepsin E and D led to the 
identification of preferable residues at different positions that can help in designing of 
specific substrates or selective inhibitors for cathepsin E or D. 
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6.2 Future perspectives 
The findings of the present work may facilitate further studies regarding cathepsin E and D or 
other proteases that exhibit similar enzymatic characteristics. E.g., the assay that was developed 
to distinctly measure the activity of CatE and CatD in biological samples is flexible and can be 
used for discriminating activity of other proteinases with similar enzymatic properties.  
The present study has also described PepA-penetratin (PepA-P) conjugate that can serve as an 
important new tool to investigate the role of aspartic proteinases in antigen processing and 
presentation in different antigen presenting cells.  
Moreover, the current thesis provides the detailed specificity information for cathepsin E and D 
that can give clues about biological functions of the two proteases and may facilitate the 
designing of specific substrates and selective inhibitors.  
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